Sök Bilder Maps Play YouTube Nyheter Gmail Drive Mer »
Logga in
Använder du ett skärmläsningsprogram? Öppna boken i tillgänglighetsläge genom att klicka här. Tillgänglighetsläget har samma grundläggande funktioner men fungerar bättre ihop med skärmläsningsprogrammet.

Patent

  1. Avancerad patentsökning
PublikationsnummerUS6096070 A
Typ av kungörelseBeviljande
AnsökningsnummerUS 08/645,646
Publiceringsdatum1 aug 2000
Registreringsdatum16 maj 1996
Prioritetsdatum7 jun 1995
AvgiftsstatusBetald
Även publicerat somDE69623855D1, DE69623855T2, EP0747069A2, EP0747069A3, EP0747069B1, US5609629
Publikationsnummer08645646, 645646, US 6096070 A, US 6096070A, US-A-6096070, US6096070 A, US6096070A
UppfinnareAnthony O. Ragheb, Brian L. Bates, Neal E. Fearnot, Thomas G. Kozma, William D. Voorhees, III
Ursprunglig innehavareMed Institute Inc., Cook Inc.
Exportera citatBiBTeX, EndNote, RefMan
Externa länkar: USPTO, Överlåtelse av äganderätt till patent som har registrerats av USPTO, Espacenet
Coated implantable medical device
US 6096070 A
Sammanfattning
A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one layer 18 of a bioactive material posited on one surface of structure 12; and at least one porous layer 20 posited over the bioactive material layer 18 posited on one surface of structure (12) and the bioactive-material-free surface. Preferably, the structure 12 is a coronary stent. The porous layer 20 is comprised of a polymer applied preferably by vapor or plasma deposition and provides a controlled release of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, merely by condensation of a monomer vapor. Also disclosed is the method of manufacture of the device 10, as well as a method of using it in medical treatments.
Bilder(4)
Previous page
Next page
Anspråk(33)
What is claimed is:
1. An implantable medical device (10), comprising:
a structure (12) adapted for introduction into a patient, the structure (12) having at least one surface and being composed of a base material (14);
at least one layer (18) of a first bioactive material posited on one surface of the structure (12); and
at least one porous layer (20) posited over the bioactive material layer (18), wherein said at least one porous layer (20) is composed of a polymer and said polymer provides for a controlled release of the bioactive material through said at least one porous layer.
2. The device (10) of claim 1, wherein the at least one porous layer (20) is one polymerized from a catalyst-free monomer vapor.
3. The device (10) of claim 1, wherein the polymer is selected from the group consisting of a polyamide, polymers of parylene or derivatives thereof, poly(ethylene oxide), poly(ethylene glycol), poly(propylene oxide), silicone based polymers, polymers of methane, tetrafluoroethylene or tetramethyldisiloxane or a polymer derived from photopolymerizeable monomers.
4. The device (10) of claim 3, wherein the thickness of the at least one porous layer (20) is about 5,000 to 250,000 Å.
5. The device (10) of claim 1, further comprising at least one additional coating layer (16) between the structure (12) and the at least one bioactive material layer (18).
6. An implantable medical device (10), comprising:
a structure (12) adapted for introduction into a patient, the structure (12) having at least one surface and being comprised of a base material (14);
at least one layer (18) of a bioactive material posited on the at least one surface of the structure (12);
at least one porous layer (20) posited over the bioactive material layer (18), wherein the at least one porous layer (20) is comprised of a polymer and said polymer provides for a controlled release of the bioactive material therethrough; and
at least one additional coating layer (16) between the structure (12) and the at least one bioactive material layer (18);
wherein the at least one additional coating layer (16) is less porous than, but comprised of the same polymer as, the at least one porous layer (20).
7. The device (10) of claim 6, wherein the polymer is selected from the group consisting of polyamide, polymers of parylene or derivatives thereof, or a polymer derived from photopolymerizable monomers of bisphenol A diglycidyl ether and acrylic acid or methacrylic acid, and the at least one additional coating layer (16) is about 50,000 to 500,000 Å thick.
8. The device (10) of claim 1, wherein the structure (12) is configured as a vascular stent.
9. The device (10) of claim 1, wherein the structure (12) is configured as at least one of: a stent, a vascular or other graft, a vascular or other graft in combination with a stent, heart valve, an orthopedic device, appliance, implant or replacement, or portion thereof; or a portion of any of these.
10. The device (10) of claim 1, wherein the base material (14) is biocompatible.
11. The device (10) of claim 10, wherein the base material (14) of the structure (12) is selected from the group consisting of stainless steel, tantalum, titanium, Nitinol, gold, platinum, inconel, iridium, silver, tungsten, or another biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers thereof; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxy-butyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a mixture thereof.
12. The device (10) of claim 1, wherein the bioactive material includes at least one of: heparin, covalent heparin, or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator; an antimicrobial agent or antibiotic; aspirin, ticlopidine, a glycoprotein IIb/IIIa inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor, dimethyl sulfoxide (DMSO), a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; or a remodeling inhibitor; deoxyribonucleic acid, an antisense nucleotide or another agent for molecular genetic intervention; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen citrate, Taxol® or derivatives thereof, or other anti-cancer chemotherapeutic agents; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal anti-inflammatory agent; cyclosporin or another immunosuppressive agent; trapidal (a PDGF antagonist), angiogenin, angiopeptin (a growth hormone antagonist), a growth factor or an anti-growth factor antibody, or another growth factor antagonist; dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist; 60 Co, 192 Ir, 32 P, 111 In, 90 Y, 99m Tc or another radiotherapeutic agent; iodine-containing compounds, barium-containing compounds, gold, tantalum, platinum, tungsten or another heavy metal functioning as a radiopaque agent; a peptide, a protein, an enzyme, an extracellular matrix component, a cellular component or another biologic agent; captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor; ascorbic acid, alpha tocopherol, superoxide dismutase, deferoxamine, a 21-amino steroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant; a 14 C-, 3 H-, 131 I-, 32 P- or 36 S-radiolabelled form or other radiolabelled form of any of the foregoing; estrogen or another sex hormone; AZT or other antipolymerases; acyclovir, famciclovir, rimantadine hydrochloride, ganciclovir sodium or other antiviral agents; 5-aminolevulinic acid, meta-tetrahydroxyphenylchlorin, hexadecafluoro zinc phthalocyanine, tetramethyl hematoporphyrin, rhodamine 123 or other photodynamic therapy agents; an IgG2 Kappa antibody against Pseudomonas aeruginosa exotoxin A and reactive with A431 epidermoid carcinoma cells, monoclonal antibody against the noradrenergic enzyme dopamine beta-hydroxylase conjugated to saporin or other antibody targeted therapy agents; gene therapy agents; and enalapril and other prodrugs, or a mixture of any of these.
13. The device (10) of claim 1, wherein the at least one layer (18) of bioactive material comprise about 0.01 to 4 mg of the bioactive material per cm2 of the gross surface area of the structure (12).
14. The device (10) of claim 1, wherein the structure (12) has a plurality of surfaces, and different bioactive materials are posited on the surfaces of the structure (12).
15. The device (10) of claim 1, wherein a different and second bioactive material is posited on the porous layer (20) and forms an outermost layer for the structure (20).
16. The device of claim 15, wherein a different and third bioactive material is posited on a bioactive-material-free surface of the structure (12), the at least one porous layer (20) being posited over the first bioactive material and a third bioactive material; and wherein the second bioactive material forming the outermost layer is covalent heparin bound to the at least one porous layer (20).
17. The device of claim 1 wherein the structure (12) comprises either a single bioactive material on one surface of said structure (12) or different bioactive materials on the different surfaces of said structure (12) with a the at least one porous layer (20) over said single first bioactive material or said different bioactive materials and said second bioactive material forms the outermost layer over said at least one porous layer (12).
18. The device (10) of claim 1, wherein the structure (12) has a plurality of different surfaces, and wherein individual ones of a plurality of layers of different bioactive materials are posited on the different surfaces of the structure (12), wherein a same bioactive material is not posited on the different surfaces of the structure (12) within the same individual one of the plurality of layers of bioactive material, and wherein either a porous layer or a bioactive material layer may form an outermost layer for the structure (12).
19. The device (10) of claim 1 wherein said bioactive material (18) is posited on said one surface of structure (12) in a geometric pattern.
20. The device (10) of claim 19 wherein said device is a stent and said bioactive material (18) is posited on said at least one surface of the stent in a discontinuous geometric pattern.
21. The device (10) of claim 20 wherein said bioactive material (18) is posited on said at least one surface of the stent in a pattern of parallel lines or wherein said stent is a vascular stent in its flattened state wherein said stent having arms attached and extending from a spine and wherein said arms having tips at a point furthest from the attachment of said arms to said spine, wherein said bioactive material is not posited on the tips of the arms of said stent.
22. The device of claim 1 wherein two or more different bioactive materials (18) are posited on said at least one surface of the structure (12).
23. The device (10) of claim 22 wherein the two or more bioactive materials (18) are posited on adjacent areas of the said at least one surface of the structure (12).
24. The device (10) of claim 1, further comprising a connector (26) securing the at least one porous layer (20) to the base material (14) of the structure (12).
25. An implantable medical device, comprising:
a structure adapted for introduction into a patient, the structure having at least one surface and being comprised of a base material; wherein the base material comprises apertures within a surface of the base material and containing at least one bioactive material within said apertures; wherein at least one porous layer is posited over said base material and said at least one bioactive material contained within said apertures; and wherein said at least one porous layer is comprised of a polymer and said polymer provides for a controlled release of the at least one bioactive material.
26. The medical device of claim 25 wherein said apertures are selected from the group consisting essentially of holes, slots, grooves or wells and may have a sectional shape of a half circle, a letter V or a truncated square.
27. The medical device of claim 26 wherein said holes, slots, grooves or wells may be formed by etching using a photo resist pattern; by cutting with laser or EBM; or by stamping.
28. The medical device of claim 27 wherein different bioactive materials are contained within the holes, grooves, slots or wells.
29. The medical device of claim 28 wherein the at least one bioactive material is selected from the group consisting essentially of heparin, covalent heparin or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator; an antimicrobial agent or antibiotic; aspirin, ticlopidine, a glycoprotein IIb/IIIa inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor, dimethylsulfoxide (DMSO), a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; or a remodeling inhibitor; deoxyribonucleic acid, an antisense nucleotide or another agent for molecular genetic intervention; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen citrate, Taxol® or derivatives thereof, or other anti-cancer chemotherapeutic agents; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal anti-inflammatory agent; cyclosporin or another immunosuppressive agent; tripodal (aPDGF antagonist), angiopeptin (a growth hormone antagonist), angiogenin or other growth factors, or an anti-growth factor antibody, or another growth factor antagonist; dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist; 60 Co, 192 Ir, 32 P, 111 In, 90 Y, 99m Tc or another radiotherapeutic agent; iodine-containing compounds, barium-containing compounds, gold, tantalum, platinum, tungsten or another heavy metal functioning as a radiopaque agent; a peptide, a protein, an enzyme, an extracellular matrix component, a cellular component or another biologic agent; captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor; ascorbic acid, alpha tocopherol, superoxide dismutase, deferoxamine, a 21-amino steroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant; a 14 C-, 3 H-, 131 I-, 32 P- or 36 S-radiolabelled form or other radiolabelled form of any of the foregoing; estrogen or another sex hormone; AZT or other antipolymerases; acyclovir, famciclovir, rimantadine hydrochloride, ganciclovir sodium or other antiviral agents; 5-aminolevulinic acid, meta-tetrahydroxyphenylchlorin, hexadecaflouoro zinc phthalocyanine, tetramethyl hematoporphyrin, rhodamine 123 or other photodynamic therapy agents; an IgG2 Kappa antibody against Pseudomonas aeruginosa exotoxin A and reactive with A431 epidermoid carcinoma cells, monoclonal antibody against the noradrenergic enzyme dopamine betahydroxylase conjugated to saporin or other antibody target therapy agents; enalapril or other prodrugs; and gene therapy agents, or a mixture of any of these.
30. An implantable medical device comprising:
a structure adapted for introduction into a patient, the structure having at least one surface and being comprised of a base material; wherein the base material comprises apertures within a surface of the base material and having at least one bioactive material within said apertures; wherein at least one porous layer is posited over said base material and said at least one bioactive material is contained within said apertures; and wherein said at least one porous, layer is comprised of a polymer and said polymer provides for a controlled release of said at least one bioactive material;
wherein said apertures are selected from the group consisting of holes, slots, grooves or wells and may have a sectional shape of a half circle, a letter V or a truncated square; and
wherein the base material comprises a substantially non-porous coating, and said at least one porous layer overlies the holes, grooves, slots or wells containing said at least one bioactive material.
31. The medical device of claim 30 wherein said device further comprises layers of bioactive materials and porous layer coatings.
32. The device (10) of claim 5, wherein at least one additional coating layer is less porous than, but composed of a different polymer as, the at least one porous layer (20).
33. The medical device of claim 26 wherein said apertures have a cross sectional shape selected from the group consisting essentially of a half circle, a letter V, or a truncated square.
Beskrivning
CROSS-REFERENCE TO RELATED COPENDING APPLICATION

This application is a continuation-in-part of application Ser. No. 08/484,532 filed on Jun. 7, 1995, now U.S. Pat. No. 5,609,629.

TECHNICAL FIELD

This invention relates generally to human and veterinary medical devices, and more particularly to devices incorporating drugs or bioactive agents.

BACKGROUND OF THE INVENTION

It has become common to treat a variety of medical conditions by introducing an implantable medical device partly or completely into the esophagus, trachea, colon, biliary tract, urinary tract, vascular system or other location within a human or veterinary patient. For example, many treatments of the vascular system entail the introduction of a device such as a stent, a catheter, a balloon, a wire guide, a cannula, or the like. However, when such a device is introduced into and manipulated through the vascular system, the blood vessel walls can be disturbed or injured. Clot formation or thrombosis often results at the injured site, causing stenosis or occlusion of the blood vessel. Moreover, if the medical device is left within the patient for an extended period of time, thrombus often forms on the device itself, again causing stenosis or occlusion. As a result, the patient is placed at risk of a variety of complications, including heart attack, pulmonary embolism, and stroke. Thus, the use of such a medical device can entail the risk of precisely the problems that its use was intended to ameliorate.

Another way in which blood vessels undergo stenosis is through disease. Probably the most common disease causing stenosis of blood vessels is atherosclerosis. Atherosclerosis is a condition which commonly affects the coronary arteries, the aorta, the iliofemoral arteries and the carotid arteries. Atherosclerotic plaques of lipids, fibroblasts, and fibrin proliferate and cause obstruction of an artery or arteries. As the obstruction increases, a critical level of stenosis is reached, to the point where the flow of blood past the obstruction is insufficient to meet the metabolic needs of the tissue distal to (downstream of) the obstruction. The result is ischemia.

Many medical devices and therapeutic methods are known for the treatment of atherosclerotic disease. One particularly useful therapy for certain atherosclerotic lesions is percutaneous transluminal angioplasty (PTA). During PTA, a balloon-tipped catheter is inserted in a patient's artery, the balloon being deflated. The tip of the catheter is advanced to the site of the atherosclerotic plaque to be dilated. The balloon is placed within or across the stenotic segment of the artery, and then inflated. Inflation of the balloon "cracks" the atherosclerotic plaque and expands the vessel, thereby relieving the stenosis, at least in part.

While PTA presently enjoys wide use, it suffers from two major problems. First, the blood vessel may suffer acute occlusion immediately after or within the initial hours after the dilation procedure. Such occlusion is referred to as "abrupt closure." Abrupt closure occurs in perhaps five percent or so of the cases in which PTA is employed, and can result in myocardial infarction and death if blood flow is not restored promptly. The primary mechanisms of abrupt closures are believed to be elastic recoil, arterial dissection and/or thrombosis. It has been postulated that the delivery of an appropriate agent (such as an antithrombic) directly into the arterial wall at the time of angioplasty could reduce the incidence of thrombotic acute closure, but the results of attempts to do so have been mixed.

A second major problem encountered in PTA is the re-narrowing of an artery after an initially successful angioplasty. This re-narrowing is referred to as "restenosis" and typically occurs within the first six months after angioplasty. Restenosis is believed to arise through the proliferation and migration of cellular components from the arterial wall, as well as through geometric changes in the arterial wall referred to as "remodeling." It has similarly been postulated that the delivery of appropriate agents directly into the arterial wall could interrupt the cellular and/or remodeling events leading to restenosis. However, like the attempts to prevent thrombotic acute closure, the results of attempts to prevent restenosis in this manner have been mixed.

Non-atherosclerotic vascular stenosis may also be treated by PTA. For example, Takayasu arteritis or neurofibromatosis may cause stenosis by fibrotic thickening of the arterial wall. Restenosis of these lesions occurs at a high rate following angioplasty, however, due to the fibrotic nature of the diseases. Medical therapies to treat or obviate them have been similarly disappointing.

A device such as an intravascular stent can be a useful adjunct to PTA, particularly in the case of either acute or threatened closure after angioplasty. The stent is placed in the dilated segment of the artery to mechanically prevent abrupt closure and restenosis. Unfortunately, even when the implantation of the stent is accompanied by aggressive and precise antiplatelet and anticoagulation therapy (typically by systemic administration), the incidence of thrombotic vessel closure or other thrombotic complication remains significant, and the prevention of restenosis is not as successful as desired. Furthermore, an undesirable side effect of the systemic antiplatelet and anticoagulation therapy is an increased incidence of bleeding complications, most often at the percutaneous entry site.

Other conditions and diseases are treatable with stents, catheters, cannulae and other devices inserted into the esophagus, trachea, colon, biliary tract, urinary tract and other locations in the body, or with orthopedic devices, implants, or replacements. It would be desirable to develop devices and methods for reliably delivering suitable agents, drugs or bioactive materials directly into a body portion during or following a medical procedure, so as to treat or prevent such conditions and diseases, for example, to prevent abrupt closure and/or restenosis of a body portion such as a passage, lumen or blood vessel. As a particular example, it would be desirable to have devices and methods which can deliver an antithrombic or other medication to the region of a blood vessel which has been treated by PTA, or by another interventional technique such as atherectomy, laser ablation, or the like. It would also be desirable that such devices would deliver their agents over both the short term (that is, the initial hours and days after treatment) and the long term (the weeks and months after treatment). It would also be desirable to provide precise control over the delivery rate for the agents, drugs or bioactive materials, and to limit systemic exposure to them. This would be particularly advantageous in therapies involving the delivery of a chemotherapeutic agent to a particular organ or site through an intravenous catheter (which itself has the advantage of reducing the amount of agent needed for successful treatment), by preventing stenosis both along the catheter and at the catheter tip. A wide variety of other therapies could be similarly improved. Of course, it would also be desirable to avoid degradation of the agent, drug or bioactive material during its incorporation on or into any such device.

SUMMARY OF THE INVENTION

The foregoing problems are solved and a technical advance is achieved in an illustrative vascular stent or other implantable medical device that provides a controlled release of an agent, drug or bioactive material into the vascular or other system, or other location in the body, in which a stent or other device is positioned. Applicants have discovered that the degradation of an agent, a drug or a bioactive material applied to such a device may be avoided by covering the agent, drug or bioactive material with a porous layer of a biocompatible polymer that is applied without the use of solvents, catalysts, heat or other chemicals or techniques, which would otherwise be likely to degrade or damage the agent, drug or material. Those biocompatible polymers may be applied preferably by vapor deposition or plasma deposition, and may polymerize and cure merely upon condensation from the vapor phase, or may be photolytically polymerizable and are expected to be useful for this purpose. However, it should be recognized that other coating techniques may also be employed.

In a first aspect, then, the present invention is directed in its simplest form to an implantable medical device comprising a structure adapted for introduction into the esophagus, trachea, colon, biliary tract, urinary tract, vascular system or other location in a human or veterinary patient, the structure being composed of a base material; at least one layer of a bioactive material posited on one surface of the structure or posited in wells, holes, grooves, slots and the like contained in the structure; and at least one porous layer posited over the bioactive material layer and the bioactive-material-free surface, the porous layer being composed of a polymer and having a thickness adequate to provide a controlled release of the bioactive material.

Preferably, when the device is intended for use in the vascular system, the bioactive material in the at least one layer is heparin or another antiplatelet or antithrombotic agent, or dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, or another dexamethasone derivative or anti-inflammatory steroid. Furthermore, a wide range of other bioactive materials can be employed, including, but not limited to, the following categories of agents: thrombolytics, vasodilators, antihypertensive agents, antimicrobials or antibiotics, antimitotics, antiproliferatives, antisecretory agents, non-steroidal anti-inflammatory drugs, immunosuppressive agents, growth factors and growth factor antagonists, antitumor and/or chemotherapeutic agents, antipolymerases, antiviral agents, photodynamic therapy agents, antibody targeted therapy agents, prodrugs, sex hormones, free radical scavengers, antioxidants, biologic agents, radiotherapeutic agents, radiopaque agents and radiolabelled agents. The major restriction is that the bioactive material must be able to withstand the coating techniques, for example, the vacuum employed during vapor deposition or plasma deposition of the at least one porous layer. In other words, the bioactive material must have a relatively low vapor pressure at the deposition temperature, typically, near or at room temperature.

The at least one porous layer is preferably composed of a polyamide, parylene or a parylene derivative applied by catalyst-free vapor deposition and is conveniently about 5,000 to 250,000 Å thick, which is adequate to provide a controlled release of the bioactive material. "Parylene" is both a generic name for a known group of polymers based on p-xylylene and made by vapor phase polymerization, and a name for the unsubstituted form of the polymer; the latter usage is employed herein. More particularly, parylene or a parylene derivative is created by first heating p-xylene or a suitable derivative at an appropriate temperature (for example, at about 950° C.) to produce the cyclic dimer di-p-xylylene (or a derivative thereof). The resultant solid can be separated in pure form, and then cracked and pyrolyzed at an appropriate temperature (for example, at about 680° C.) to produce a monomer vapor of p-xylylene (or derivative); the monomer vapor is cooled to a suitable temperature (for example, below 50° C.) and allowed to condense on the desired object, for example, on the at least one layer of bioactive material. The resultant polymer has the repeating structure .paren open-st.CH2 C6 H4 CH2 .paren close-st.n, with n equal to about 5,000, and a molecular weight in the range of 500,000.

As indicated, parylene and parylene derivative coatings applicable by vapor deposition are known for a variety of biomedical uses, and are commercially available from or through a variety of sources, including Specialty Coating Systems (100 Deposition Drive, Clear Lake, Wis. 54005), Para Tech Coating, Inc. (35 Argonaut, Aliso Viejo, Calif. 92656) and Advanced Surface Technology, Inc. (9 Linnel Circle, Billerica, Mass. 01821-3902).

The at least one porous layer can alternatively be applied by plasma deposition. Plasma is an ionized gas maintained under vacuum and excited by electrical energy, typically in the radiofrequency range. Because the gas is maintained under vacuum, the plasma deposition process occurs at or near room temperature. Plasma can be used to deposit polymers such as poly(ethylene oxide), poly(ethylene glycol), and poly(propylene oxide), as well as polymers of silicone, methane, tetrafluoroethylene (including TEFLON brand polymers), tetramethyldisiloxane, and others.

While the foregoing represents some preferred embodiments of the present invention, other polymer systems may also be employed, e.g., polymers derived from photopolymerizeable monomers. Also, other coating techniques may be utilized, e.g., dipping, spraying, and the like.

The device may include two or more layers of different bioactive materials atop the structure. However, for the purposes of the present invention, the same bioactive material will generally not be posited on the different surfaces of the device within the same layer. In other words, each surface of the device structure will carry a different bioactive material or materials except where the bioactive material is the innermost or outermost layer, e.g. heparin may form the innermost layer or the outermost layer or both. These additional layers may be placed directly atop one another or can be separated by additional porous polymer layers between each of them. Additionally, the layers of bioactive materials can comprise a mixture of different bioactive materials. The porous layers are also preferably composed of parylene or a parylene derivative. Advantageously, the two or more bioactive materials can have different solubilities, and the layer containing the less soluble bioactive material (for example, dexamethasone) is preferably posited above the layer containing the more soluble bioactive material (for example, heparin). Unexpectedly, this has been found to increase the in vitro release rate of some relatively less soluble materials such as dexamethasone, while simultaneously decreasing the release rate of some relatively more soluble materials such as heparin.

While the structure included in the device may be configured in a variety of ways, the structure is preferably configured as a vascular stent composed of a biocompatible metal such as stainless steel, nickel, silver, platinum, gold, titanium, tantalum, iridium, tungsten, Nitinol, inconel, or the like. An additional substantially nonporous coating layer of parylene or a parylene derivative or other biocompatible polymer of about 50,000 to 500,000 Å thick may be posited directly atop the vascular stent, beneath the at least one layer of bioactive material. The additional coating layer can merely be relatively less porous than the at least one porous layer, but preferably is substantially nonporous, that is, sufficiently nonporous to render the stent essentially impervious to blood during normal circumstances of use.

In a second aspect, the present invention is directed to a method of making an implantable medical device of the type disclosed above, in which the method comprises the steps of: depositing at least one layer of a bioactive material on one surface of the structure; and depositing at least one porous layer over the at least one bioactive material layer and the bioactive-material-free surface, the at least one porous layer being composed of a polymer and being of a thickness adequate to provide a controlled release of the bioactive material. Conveniently and in a preferred embodiment, the at least one porous layer is polymerized from a monomer vapor which is free of any solvent or polymerization catalyst, and cures by itself upon condensation, without any additional heating or curing aid (for example, visible or ultraviolet light). The at least one layer of the bioactive material may be deposited on the one surface of the structure by any convenient method such as dipping, rolling, brushing, spraying, electrostatic deposition, or the like.

Lastly, in a third aspect, the present invention is directed to an improvement in a method of medically treating a human or veterinary patient by the step of inserting an implantable medical device into the body of the patient, the device comprising a structure adapted for introduction into an applicable system of or location in the patient, and the structure being composed of a base material, in which the procedure comprises the preliminary steps of: depositing at least one layer of a bioactive material on one surface of the structure; and depositing at material layer and the bioactive-material-free surface, the at least one porous layer being composed of a polymer having a thickness adequate to provide a controlled release of the bioactive material.

The device and methods of the present invention are useful in a wide variety of locations within a human or veterinary patient, such as in the esophagus, trachea, colon, biliary tract, urinary tract and vascular system, as well as for subdural and orthopedic devices, implants or replacements. They are particularly advantageous for reliably delivering suitable bioactive materials during or following an intravascular procedure, and find particular use in preventing abrupt closure and/or restenosis of a blood vessel. More particularly, they permit, for example, the delivery of an antithrombotic, an antiplatelet, an anti-inflammatory steroid, or another medication to the region of a blood vessel which has been opened by PTA. Likewise, it allows for the delivery of one bioactive material to, for example, the lumen of a blood vessel and another bioactive material to the vessel wall. The use of a porous polymer layer permits the release rate of a bioactive material to be carefully controlled over both the short and long terms.

These and other aspects of the present invention will be appreciated by those skilled in the art upon the reading and understanding of the specification.

BRIEF DESCRIPTION OF THE DRAWING

A better understanding of the present invention will now be had upon reference to the following detailed description, when read in conjunction with the accompanying drawing, wherein like reference characters refer to like parts throughout the several views, and in which:

FIG. 1 is a cross-sectional view of a first preferred embodiment of the present invention;

FIG. 2 is a cross-sectional view of another preferred embodiment of the present invention;

FIG. 3 is a cross-sectional view of yet another preferred embodiment of the present invention;

FIG. 4 is a cross-sectional view of a further preferred embodiment of the present invention;

FIG. 5 is a cross-sectional view of an additional preferred embodiment of the present invention;

FIGS. 6A and 6B are cross-sectional views of an additional preferred embodiment of the present invention;

FIG. 7 is a cross-sectional view of an additional preferred embodiment of the present invention;

FIG. 8 is a partial, enlarged top view of FIG. 7;

FIG. 9 is an enlarged, sectional view along lines 9--9 of FIG. 8; and

FIGS. 10A-10D are enlarged cross-sectional views along lines 10--10 of FIG. 8.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

With reference now to FIG. 1, an implantable medical device 10 in accordance with the present invention is shown and first comprises a structure 12 adapted for introduction into a human or veterinary patient. "Adapted" means that the structure 12 is shaped and sized for such introduction. For clarity, only a portion of the structure 12 is shown in FIG. 1.

By way of example, the structure 12 is configured as a vascular stent particularly adapted for insertion into the vascular system of the patient. However, this stent structure can be used in other systems and sites such as the esophagus, trachea, colon, biliary ducts, urethra and ureters, subdural among others. Indeed, the structure 12 can alternatively be configured as any conventional vascular or other medical device, and can include any of a variety of conventional stents or other adjuncts, such as helical wound strands, perforated cylinders, or the like. Moreover, because the problems addressed by the present invention arise with respect to those portions of the device actually positioned within the patient, the inserted structure 12 need not be an entire device, but can merely be that portion of a vascular or other device which is intended to be introduced into the patient. Accordingly, the structure 12 can be configured as at least one of, or any portion of, a catheter, a wire guide, a cannula, a stent, a vascular or other graft, a cardiac pacemaker lead or lead tip, a cardiac defibrillator lead or lead tip, a heart valve, or an orthopedic device, appliance, implant, or replacement. The structure 12 can also be configured as a combination of portions of any of these.

Most preferably, however, the structure 12 is configured as a vascular stent such as the commercially available Gianturco-Roubin FLEX-STENT coronary stent from Cook Incorporated, Bloomington, Ind. Such stents are typically about 10 to about 60 mm in length and designed to expand to a diameter of about 2 to about 6 mm when inserted into the vascular system of the patient. The Gianturco-Roubin stent in particular is typically about 12 to about 25 mm in length and designed to expand to a diameter of about 2 to about 4 mm when so inserted.

These stent dimensions are, of course, applicable to exemplary stents employed in the coronary arteries. Structures such as stents or catheter portions intended to be employed at other sites in the patient, such as in the aorta, esophagus, trachea, colon, biliary tract, or urinary tract will have different dimensions more suited to such use. For example, aortic, esophageal, tracheal and colonic stents may have diameters up to about 25 mm and lengths about 100 mm or longer.

The structure 12 is composed of a base material 14 suitable for the intended use of the structure 12. The base material 14 is preferably biocompatible, although cytotoxic or other poisonous base materials may be employed if they are adequately isolated from the patient. Such incompatible materials may be useful in, for example, radiation treatments in which a radioactive material is positioned by catheter in or close to the specific tissues to be treated. Under most circumstances, however, the base material 14 of the structure 12 should be biocompatible.

A variety of conventional materials can be employed as the base material 14. Some materials may be more useful for structures other than the coronary stent exemplifying the structure 12. The base material 14 may be either elastic or inelastic, depending upon the flexibility or elasticity of the polymer layers to be applied over it. The base material may be either biodegradable or non-biodegradable, and a variety of biodegradable polymers are known. Moreover, some biologic agents have sufficient strength to serve as the base material 14 of some useful structures 12, even if not especially useful in the exemplary coronary stent.

Accordingly, the base material 14 can include at least one of stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, silver, tungsten, or another biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers of these; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a suitable mixture of any of these. Stainless steel is particularly useful as the base material 14 when the structure 12 is configured as a vascular stent.

Of course, when the structure 12 is composed of a radiolucent material such as polypropylene, polyethylene, or others above, a conventional radiopaque coating may and preferably should be applied to it. The radiopaque coating provides a means for identifying the location of the structure 12 by X-ray or fluoroscopy during or after its introduction into the patient's vascular system.

With continued reference to FIG. 1, the vascular device 10 of the present invention next comprises at least one layer 18 of a bioactive material posited on one surface of the structure 12. For the purposes of the present invention, at least one bioactive material is posited on one surface of the structure 12, and the other surface will either contain no bioactive material or one or more different bioactive materials. In this manner, one or more bioactive materials or drugs may be delivered, for example, with a vascular stent, to the blood stream from the lumen surface of the stent, and a different treatment may be delivered on the vessel surface of the stent. A vast range of drugs, medicaments and materials may be employed as the bioactive material in the layer 18, so long as the selected material can survive exposure to the vacuum drawn during vapor deposition or plasma deposition. Particularly useful in the practice of the present invention are materials which prevent or ameliorate abrupt closure and restenosis of blood vessels previously opened by stenting surgery or other procedures. Thrombolytics (which dissolve, break up or disperse thrombi) and antithrombogenics (which interfere with or prevent the formation of thrombi) are especially useful bioactive materials when the structure 12 is a vascular stent. Particularly preferred thrombolytics are urokinase, streptokinase, and the tissue plasminogen activators. Particularly preferred antithrombogenics are heparin, hirudin, and the antiplatelets.

Urokinase is a plasminogen activating enzyme typically obtained from human kidney cell cultures. Urokinase catalyzes the conversion of plasminogen into the fibrinolytic plasmin, which breaks down fibrin thrombi.

Heparin is a mucopolysaccharide anticoagulant typically obtained from porcine intestinal mucosa or bovine lung. Heparin acts as a thrombin inhibitor by greatly enhancing the effects of the blood's endogenous antithrombin III. Thrombin, a potent enzyme in the coagulation cascade, is key in catalyzing the formation of fibrin. Therefore, by inhibiting thrombin, heparin inhibits the formation of fibrin thrombi. Alternatively, heparin may be covalently bound to the outer layer of structure 12. Thus, heparin would form the outermost layer of structure 12 and would not be readily degraded enzymatically, and would remain active as a thrombin inhibitor.

Of course, bioactive materials having other functions can also be successfully delivered by the device 10 of the present invention. For example, an antiproliferative agent such as methotrexate will inhibit over-proliferation of smooth muscle cells and thus inhibit restenosis of the dilated segment of the blood vessel. The antiproliferative is desirably supplied for this purpose over a period of about four to six months. Additionally, localized delivery of an antiproliferative agent is also useful for the treatment of a variety of malignant conditions characterized by highly vascular growth. In such cases, the device 10 of the present invention could be placed in the arterial supply of the tumor to provide a means of delivering a relatively high dose of the antiproliferative agent directly to the tumor.

A vasodilator such as a calcium channel blocker or a nitrate will suppress vasospasm, which is common following angioplasty procedures. Vasospasm occurs as a response to injury of a blood vessel, and the tendency toward vasospasm decreases as the vessel heals. Accordingly, the vasodilator is desirably supplied over a period of about two to three weeks. Of course, trauma from angioplasty is not the only vessel injury which can cause vasospasm, and the device 10 may be introduced into vessels other than the coronary arteries, such as the aorta, carotid arteries, renal arteries, iliac arteries or peripheral arteries for the prevention of vasospasm in them.

A variety of other bioactive materials are particularly suitable for use when the structure 12 is configured as something other than a coronary stent. For example, an anti-cancer chemotherapeutic agent can be delivered by the device 10 to a localized tumor. More particularly, the device 10 can be placed in an artery supplying blood to the tumor or elsewhere to deliver a relatively high and prolonged dose of the agent directly to the tumor, while limiting systemic exposure and toxicity. The agent may be a curative, a pre-operative debulker reducing the size of the tumor, or a palliative which eases the symptoms of the disease. It should be noted that the bioactive material in the present invention is delivered across the device 10, and not by passage from an outside source through any lumen defined in the device 10, such as through a catheter employed for conventional chemotherapy. The bioactive material of the present invention may, of course, be released from the device 10 into any lumen defined in the device, or to tissue in contact with the device and that the lumen may carry some other agent to be delivered through it. For example, tamoxifen citrate, Taxol® or derivatives thereof Proscar®, Hytrin®, or Eulexin® may be applied to the tissue-exposed surface of the device for delivery to a tumor located, for example in breast tissue or the prostate.

Dopamine or a dopamine agonist such as bromocriptine mesylate or pergolide mesylate is useful for the treatment of neurological disorders such as Parkinson's disease. The device 10 could be placed in the vascular supply of the thalamic substantia nigra for this purpose, or elsewhere, localizing treatment in the thalamus.

A wide range of other bioactive materials can be delivered by the device 10. Accordingly, it is preferred that the bioactive material contained in the layer 18 includes at least one of heparin, covalent heparin, or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator; Hytrin® or other antihypertensive agents; an antimicrobial agent or antibiotic; aspirin, ticlopidine, a glycoprotein IIb/IIIa inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor, dimethyl sulfoxide (DMSO), a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; or a remodelling inhibitor; deoxyribonucleic acid, an antisense nucleotide or another agent for molecular genetic intervention; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen citrate, Taxol® or the derivatives thereof, or other anti-cancer chemotherapeutic agents; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal anti-inflammatory agent; cyclosporin or another immunosuppressive agent; trapidal (a PDGF antagonist), angiopeptin (a growth hormone antagonist), angiogenin, a growth factor or an anti-growth factor antibody, or another growth factor antagonist; dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist; 60 Co (5.3 year half life), 192 Ir (73.8 days), 32 P (14.3 days), 111 In (68 hours), 90 Y (64 hours), 99m Tc (6 hours) or another radiotherapeutic agent; iodine-containing compounds, barium-containing compounds, gold, tantalum, platinum, tungsten or another heavy metal functioning as a radiopaque agent; a peptide, a protein, an enzyme, an extracellular matrix component, a cellular component or another biologic agent; captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor; ascorbic acid, alpha tocopherol, superoxide dismutase, deferoxamine, a 21-aminosteroid (lasaroid) or another free radical scavenger, iron chelator or antioxidant; a 14 C-, 3 H-, 131 I-, 32 P- or 36 S-radiolabelled form or other radiolabelled form of any of the foregoing; estrogen or another sex hormone; AZT or other antipolymerases; acyclovir, famciclovir, rimantadine hydrochloride, ganciclovir sodium, Norvir, Crixivan, or other antiviral agents; 5-aminolevulinic acid, meta-tetrahydroxyphenylchlorin, hexadecafluoro zinc phthalocyanine, tetramethyl hematoporphyrin, rhodamine 123 or other photodynamic therapy agents; an IgG2 Kappa antibody against Pseudomonas aeruginosa exotoxin A and reactive with A431 epidermoid carcinoma cells, monoclonal antibody against the noradrenergic enzyme dopamine beta-hydroxylase conjugated to saporin or other antibody targeted therapy agents; gene therapy agents; and enalapril and other prodrugs; Proscar®, Hytrin® or other agents for treating benign prostatic hyperplasia (BHP) or a mixture of any of these; and various forms of small intestine submucosa (SIS).

In a particularly preferred aspect, the layer of bioactive material contains preferably from about 0.01 mg to about 10 mg and more preferrably from about 0.1 mg to about 4 mg of the bioactive material per cm2 of the gross surface area of the structure. "Gross surface area" refers to the area calculated from the gross or overall extent of the structure, and not necessarily to the actual surface area of the particular shape or individual parts of the structure. In other terms, about 100 μg to about 300 μg of drug per 0.001 inch of coating thickness may be contained on the device surface.

When the structure 12 is configured as a vascular stent, however, particularly preferred materials for the bioactive material of the layer 18 are heparin, anti-inflammatory steroids including but not limited to dexamethasone and its derivatives, and mixtures of heparin and such steroids.

Still with reference to FIG. 1, the device 10 of the present invention also comprises at least one porous layer 20 posited over the layer 18 of bioactive material and the bioactive-material-free surface. The purpose of the porous layer 20 is to provide a controlled release of the bioactive material when the device 10 is positioned in the vascular system of a patient. The thickness of the porous layer 20 is chosen so as to provide such control.

More particularly, the porous layer 20 is composed of a polymer deposited on the bioactive material layer 18, preferably by vapor deposition. Plasma deposition may also be useful for this purpose. Preferably, the layer 20 is one that is polymerized from a vapor which is free of any solvent, catalysts or similar polymerization promoters. Also preferably, the polymer in the porous layer 20 is one which automatically polymerizes upon condensation from the vapor phase, without the action of any curative agent or activity such as heating, the application of visible or ultraviolet light, radiation, ultrasound, or the like. Most preferably, the polymer in the porous layer 20 is polyimide, parylene or a parylene derivative.

When first deposited, the parylene or parylene derivative is thought to form a network resembling a fibrous mesh, with relatively large pores. As more is deposited, the porous layer 20 not only becomes thicker, but it is believed that parylene or parylene derivative is also deposited in the previously formed pores, making the existing pores smaller. Careful and precise control over the deposition of the parylene or parylene derivative therefore permits close control over the release rate of material from the at least one layer 18 of bioactive material. It is for this reason that the bioactive material lies under the at least one porous layer 20, rather than being dispersed within or throughout it. The porous layer 20, however, also protects the bioactive material layer 18 during deployment of the device 10, for example, during insertion of the device 10 through a catheter and into the vascular system or elsewhere in the patient.

As shown in FIG. 1, the device 10 of the present invention can further comprise at least one additional coating layer 16 posited between the structure 12 and the at least one layer 18 of bioactive material. While the additional coating layer 16 can simply be a medical grade primer, the additional coating layer 16 is preferably composed of the same polymer as the at least one porous layer 20. However, the additional coating layer 16 is also preferably less porous than the at least one porous layer 20, and is more preferably substantially nonporous. "Substantially nonporous" means that the additional coating layer 16 is sufficiently impervious to prevent any appreciable interaction between the base material 14 of the structure 12 and the blood to which the device 10 will be exposed during use. The use of an additional coating layer 16 which is substantially nonporous would permit the use of a toxic or poisonous base material 14, as mentioned above. Even if the base material 14 of the structure 12 is biocompatible, however, it may be advantageous to isolate it from the blood by use of a substantially nonporous coating layer 16.

Other polymer systems that may find application within the scope of the invention include polymers derived from photopolymerizable monomers such as liquid monomers preferably having at least two cross linkable C--C (Carbon to Carbon) double bonds and being a non-gaseous addition polymerizable ethylenically unsaturated compound, having a boiling point above 100° C., at atmospheric pressure, a molecular weight of about 100-1500 and being capable of forming high molecular weight addition polymers readily. More preferably, the monomer is preferably an addition photopolymerizable polyethylenically unsaturated acrylic or methacrylic acid ester containing two or more acrylate or methacrylate groups per molecule or mixtures thereof. A few illustrative examples of such multifunctional acrylates are ethylene glycol diacrylate, ethylene glycol dimethacrylate, trimethylopropane triacrylate, trimethylopropane trimethacrylate, pentaerythritol tetraacrylate or pentaerythritol tetramethacrylate, 1,6-hexanediol dimethacrylate, and diethyleneglycol dimethacrylate.

Also useful in some special instances are monoacrylates such as n-butyl-acrylate, n-butyl methacrylate, 2-ethylhexyl acrylate, lauryl-acrylate, and 2-hydroxy-propyl acrylate. Small quantities of amides of (meth)acrylic acid such as N-methylol methacrylamide butyl ether are also suitable, N-vinyl compounds such as N-vinyl pyrrolidone, vinyl esters of aliphatic monocarboxylic acids such as vinyl oleate, vinyl ethers of diols such as butanediol-1, 4-divinyl ether and allyl ether and allyl ester are also suitable. Also included would be other monomers such as the reaction products of di- or polyepoxides such as butanediol-1, 4-diglycidyl ether or bisphenol A diglycidyl ether with (meth)acrylic acid. The characteristics of the photopolymerizable liquid dispersing medium can be modified for the specific purpose by a suitable selection of monomers or mixtures thereof.

Other useful polymer systems include a polymer that is biocompatible and minimizes irritation to the vessel wall when the stent is implanted. The polymer may be either a biostable or a bioabsorbable polymer depending on the desired rate of release or the desired degree of polymer stability, but a bioabsorbable polymer is preferred for this embodiment since, unlike a biostable polymer, it will not be present long after implantation to cause any adverse, chronic local response. Bioabsorbable polymers that could be used include poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters) (e.g., PEO/PLA), polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid. Also, biostable polymers with a relatively low chronic tissue response such as polyurethanes, silicones, and polyesters could be used and other polymers could also be used if they can be dissolved and cured or polymerized on the stent such as polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins, polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins, polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate, cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.

While plasma deposition and vapor phase deposition may be a preferred method for applying the various coatings on the stent surfaces, other techniques may be employed. For example, a polymer solution may be applied to the stent and the solvent allowed to evaporate, thereby leaving on the stent surface a coating of the polymer and the therapeutic substance. Typically, the solution can be applied to the stent by either spraying the solution onto the stent or immersing the stent in the solution. Whether one chooses application by immersion or application by spraying depends principally on the viscosity and surface tension of the solution, however, it has been found that spraying in a fine spray such as that available from an airbrush will provide a coating with the greatest uniformity and will provide the greatest control over the amount of coating material to be applied to the stent. In either a coating applied by spraying or by immersion, multiple application steps are generally desirable to provide improved coating uniformity and improved control over the amount of therapeutic substance to be applied to the stent.

When the layer 18 of bioactive material contains a relatively soluble material such as heparin, and when the at least one porous layer 20 is composed of parylene or a parylene derivative, the at least one porous layer 20 is preferably about 5,000 to 250,000 Å thick, more preferably about 5,000 to 100,000 Å thick, and optimally about 50,000 Å thick. When the at least one additional coating layer 16 is composed of parylene or a parylene derivative, the at least one additional coating is preferably about 50,000 to 500,000 Å thick, more preferably about 100,000 to 500,000 Å thick, and optimally about 200,000 Å thick.

When the at least one layer 18 of bioactive material contains a relatively soluble material such as heparin, the at least one layer 18 preferably contains a total of about 0.1 to 4 mg of bioactive material per cm2 of the gross surface area of the structure 12. This provides a release rate for the heparin (measured in vitro) which is desirably in the range of 0.1 to 0.5 mg/cm2 per day, and preferably about 0.25 mg/cm2 per day, under typical blood flows through vascular stents. It should be noted that the solubility of dexamethasone can be adjusted as desired, with or without the inclusion of heparin, by mixing it with one or more of its relatively more soluble derivatives, such as dexamethasone sodium phosphate.

As shown in FIG. 2, the device 10 of the present invention is not limited to the inclusion of a single layer 18 of bioactive material. The device 10 can, for example, comprise a second layer 22 of a bioactive material posited over the structure 12. The bioactive material of the second layer 22 can be, but need not necessarily be, different from the bioactive material of the first bioactive material layer 18, only that they not be posited on the same surface of the device 10 without the intermediate porous layer 24. The use of different materials in the layers 18 and 22 allows the device 10 to perform more than a single therapeutic function.

The device 10 of the present invention can further comprise an additional porous layer 24 of the polymer posited between each of the layers 18 and 22 of bioactive material. It is reiterated that bioactive material 18 is on one surface of structure 12. The other surface may be free of bioactive material or may comprise one or more different bioactive materials. The additional porous layer 24 can give the bioactive materials in the layers 18 and 22 different release rates. Simultaneously, or alternatively, the device 10 may employ bioactive materials in the two layers 18 and 22 which are different from one another and have different solubilities. In such a case, it is advantageous and preferred to position the layer 22 containing the less soluble bioactive material above the layer 18 containing the more soluble bioactive material. Alternatively, the bioactive material 18 may be contained in holes, wells, slots and the like occurring within the stent surface as illustrated in FIGS. 8-10 and will further be discussed in greater detail.

For example, when the structure 12 of the device 10 is configured as a vascular stent, it is advantageous for the at least one layer 18 to contain relatively soluble heparin, and the second layer 22 to contain relatively less soluble dexamethasone. Unexpectedly, the heparin promotes the release of the dexamethasone, increasing its release rate many times over the release rate of dexamethasone in the absence of heparin. The release rate of the heparin is also lowered, somewhat less dramatically than the increase of the dexamethasone release rate. More particularly, when dexamethasone is disposed by itself beneath a porous parylene layer 20 dimensioned as disclosed above, its release rate is negligible; an adequate release rate is obtained only when the thickness of the porous layer 20 is reduced by a factor of ten or more. In contrast, when a layer 22 of dexamethasone is disposed over a layer 18 of heparin, and beneath a porous parylene layer 20 dimensioned as above, the dexamethasone may be released at a desirable rate of about 1 to 10 μg/cm2 per day. Moreover, and even more unexpectedly, this increased release rate for the dexamethasone is thought to be maintained even after all of the heparin has been released from the layer 18.

The bioactive material layers 18 and/or 22 are applied to the device 10 independent of the application of the porous polymer layers 20 and/or 24. Any mixing of a bioactive material from the layers 18 and/or 22 into the porous layers 20 and/or 24, prior to introducing the device 10 into the vascular system of the patient, is unintentional and merely incidental. This gives significantly more control over the release rate of the bioactive material than the simple dispersal of a bioactive material in a polymeric layer.

The device 10 need not include the additional porous layer 24 when two or more layers 18 and 22 of bioactive material are present. As shown in FIG. 3, the layers 18 and 22 do not have to be separated by a porous layer, but can instead lie directly against one another. It is still advantageous in this embodiment to position the layer 22 containing the relatively less soluble bioactive material above the layer 18 containing the relatively more soluble bioactive material.

Whether or not the additional porous layer 24 is present, it is preferred that the layers 18 and 22 contain about 0.05 to 2.0 mg of each of heparin and dexamethasone, respectively, per 1 cm2 of the gross surface area of the structure 12. The total amount of bioactive material posited in the layers 18 and 22 over the structure 12 is thus preferably in the range of about 0.1 to 10 mg/cm2.

Some dexamethasone derivatives, such as dexamethasone sodium phosphate, are substantially more soluble than dexamethasone itself. If a more soluble dexamethasone derivative is used as the bioactive material in the device 10 of the present invention, the thickness of the at least one porous layer 20 (and of the additional porous layer 24) should be adjusted accordingly.

The particular structure of the device 10 as disclosed may be adapted to specific uses in a variety of ways. For example, the device 10 may include further layers of the same or different bioactive materials. These additional layers of bioactive material may or may not be separated by additional porous layers, as convenient or desired. Alternatively, additional porous layers may separate only some of the additional layers of bioactive material. Moreover, one bioactive material may be placed on one portion of the structure 12 of the device 10, and another bioactive material placed on a different portion of the structure 12 of the device 10.

Alternatively, the device 10 need not include the additional coating layer 16 at all. Such a configuration is shown in FIG. 4, in which the bioactive material layer 18 is posited directly atop the base material 14 of the structure 12. In such a case, it may be highly advantageous to surface process or surface activate the base material 14, to promote the deposition or adhesion of the bioactive material on the base material 14, especially before the depositing of the at least one porous layer 20. Surface processing and surface activation can also selectively alter the release rate of the bioactive material. Such processing can also be used to promote the deposition or adhesion of the additional coating layer 16, if present, on the base material 14. The additional coating layer 16 itself, or any second or additional porous layer 24 itself, can similarly be processed to promote the deposition or adhesion of the bioactive material layer 18, or to further control the release rate of the bioactive material.

Useful methods of surface processing can include any of a variety of such procedures, including: cleaning; physical modifications such as etching, drilling, cutting, or abrasion; and chemical modifications such as solvent treatment, the application of primer coatings, the application of surfactants, plasma treatment, ion bombardment and covalent bonding.

It has been found particularly advantageous to plasma treat the additional coating layer 16 (for example, of parylene) before depositing the bioactive material layer 18 atop it. The plasma treatment improves the adhesion of the bioactive material, increases the amount of bioactive material that can be deposited, and allows the bioactive material to be deposited in a more uniform layer. Indeed, it is very difficult to deposit a hygroscopic agent such as heparin on an unmodified parylene surface, which is hydrophobic and poorly wettable. However, plasma treatment renders the parylene surface wettable, allowing heparin to be easily deposited on it.

Any of the porous polymer layers 20 and 24 may also be surface processed by any of the methods mentioned above to alter the release rate of the bioactive material or materials, and/or otherwise improve the biocompatibility of the surface of the layers. For example, the application of an overcoat of polyethylene oxide, phosphatidylcholine or a covalently bound bioactive material, e.g., covalently attached heparin to the layers 20 and/or 24 could render the surface of the layers more blood compatible. Similarly, the plasma treatment or application of a hydrogel coating to the layers 20 and/or 24 could alter their surface energies, preferably providing surface energies in the range of 20 to 30 dyne/cm, thereby rendering their surfaces more biocompatible.

Referring now to FIG. 5, an embodiment of the device 10 is there shown in which a mechanical bond or connector 26 is provided between (a) any one of the porous layers 20 and 24, and (b) any or all of the other of the porous layers 20 and 24, the additional coating layer 16 and the base material 14. The connector 26 reliably secures the layers 16, 20 and/or 24 to each other, and or to the base material 14. The connector 26 lends structural integrity to the device 10, particularly after the bioactive material layer or layers 18 and/or 20 have been fully released into the patient.

For simplicity, the connector 26 is shown in FIG. 5 as a plurality of projections of the base material 14 securing a single porous layer 20 to the base material 14. The connector 26 may alternatively extend from the porous layer 20, through the bioactive material layer 18, and to the base material 14. In either case, a single layer 18 of bioactive material, divided into several segments by the connector 26, is posited between the porous layer 20 and the base material 14. The connectors can also function to partition the different bioactive agents into different regions of the device's surface.

The connector 26 may be provided in a variety of ways. For example, the connector 26 can be formed as a single piece with the base material 14 during its initial fabrication or molding into the structure 12. The connector 26 can instead be formed as a distinct element, such as a bridge, strut, pin or stud added to an existing structure 12. The connector 26 can also be formed as a built-up land, shoulder, plateau, pod or pan on the base material 14. Alternatively, a portion of the base material 14 between the desired locations of plural connectors 26 may be removed by etching, mechanical abrasion, or the like, and the bioactive material layer 18 deposited between them. The connector 26 can also be formed so as to extend downwards towards the base material 14, by wiping or etching away a portion of a previously applied bioactive material layer 18, and allowing the porous layer 20 to deposit by vapor deposition or plasma deposition directly on the bare portions of the base material 14. Other ways to expose a portion of the base material 14 to direct connection to the porous layer 20 will be evident to those skilled in this area.

In another preferred embodiment, as illustrated in FIGS. 6A, 6B and 7, a bioactive material 18 is posited on the one surface of base material 14 making up structure 12 in FIG. 6A. FIG. 7 shows a stent 10 in its flat or planar state prior to being coiled and showing porous layer 20 applied to its outermost surface. FIGS. 6A and 6B are section views along line 6--6 of FIG. 7. The bioactive material 18 posited on the one surface of base material 14 in FIG. 6A may be a number of different therapeutic and/or diagnostic agents. For example, the device 10 may be a stent which is placed in the body of a patient near a tumor to deliver a chemotherapeutic agent, such as tamoxifen citrate or Taxol®, directly to the tumor. A porous layer 20 is posited over the bioactive material 18 to provide a smoother surface as well as a more controlled release of the bioactive material 18. As further illustrated in FIG. 6A, the opposite surface of the device may have, for example, heparin 181 covalently bonded to porous layer 20, particularly where this surface faces, for example, the lumen of a blood vessel, to provide antithrombotic effect and blood compatibility. It is pointed out, as has been discussed herein, a third but different bioactive material may be posited (not shown) on the opposite surface of base material 14 from the first bioactive material 18 and on the same side of base material 14 as the covalently bound heparin or any other bioactive material including other covalently bound bioactive materials and separated by porous layer 20.

A variation of the embodiment shown in FIG. 6A is illustrated in FIG. 6B, where two bioactive materials 18 and 18' are posited on the same surface of base material 14 of structure 12. A porous layer 20 may be deposited over the bioactive materials 18 and 18' as well as the bioactive-material-free surface of based material 14. This embodiment illustrates a situation where it may be desirable to deliver two agents to the tissue to which the particular surface of device 10 is exposed, e.g., an antiinflammatory agent and an antiviral agent. Moreover, the opposite surface of the device free of bioactive material is available for positing one or more bioactive materials or therapeutic agents, e.g., an antithrombotic agent.

As has been previously discussed, multiple layers of bioactive materials and porous layers may be applied to the device 10 where the limiting factors become the total thickness of the device, the adhesion of multiple layers and the like.

In still another embodiment of the present invention, the device of the present invention includes apertures within the device for containing the bioactive material. This embodiment is illustrated in FIGS. 8, 9, 10A, 10B, 10C and 10D. FIG. 8 shows an arm of the stent of FIG. 7 wherein the arm includes holes 28 into which a bioactive material is contained. FIG. 9 shows a section of the arm of the stent along lines 9--9 of FIG. 8. Bioactive material 18 is contained within the hole 28 where the base material 14 contains coating 16 and further where porous layer 20 forms the outer most layer for the bioactive material 18 to diffise through. In an alternative embodiment, wells 28' may be cut, etched or stamped into the base material 14 of the device in which a bioactive material 18 may be contained. This embodiment is illustrated in FIGS. 10A, 10B, 10C and 10D which are sectional FIGs. taken along line 10--10 of FIG. 8. The wells 28' may also be in the form of slots or grooves in the surface of the base material 14 of the medical device. This aspect of the invention provides the advantage of better controlling the total amount of the bioactive material 18 to be released as well as the rate at which it is released. For example, a V-shape well 28', as illustrated in FIG. 10D, will contain less quantity of bioactive material 18 and release the material at geometric rate as compared to a square shaped well 28', as illustrated in FIG. 10B, which will have a more uniform, linear release rate.

The holes, wells, slots, grooves and the like, described above, may be formed in the surface of the device 10 by a variety of techniques. For example, such techniques include drilling or cutting by utilizing lasers, electron-beam machining and the like or employing photoresist procedures and etching the desired apertures.

All the bioactive materials discussed above that may be coated on the surface of the device 10 may be used to be contained within the apertures of this aspect of the invention. Likewise, layers of bioactive materials and porous layers may be applied and built up on the exterior surfaces of the device as described previously with regard to other aspects of the invention, e.g., heparin, may be covalently bound to one surface of the device illustrated in FIG. 9.

The method of making the device 10 according to the present invention may now be understood. In its simplest form, the method comprises the steps of depositing the at least one layer 18 of bioactive material over the structure 12, followed by depositing the at least one porous layer 20, preferably by vapor deposition or plasma deposition, over the at least one bioactive material layer 18 on the one surface of structure 12. The at least one porous layer 20 being composed of a biocompatible polymer and being of a thickness adequate to provide a controlled release of the bioactive material. Preferably, the at least one additional coating layer 16 is first posited by vapor deposition directly on the base material 14 of the structure 12. Such deposition is carried out by preparing or obtaining di-p-xylylene or a derivative thereof, sublimating and cracking the di-p-xylylene or derivative to yield monomeric p-xylylene or a monomeric derivative, and allowing the monomer to simultaneously condense on and polymerize over the base material 14. The deposition step is carried out under vacuum, and the base material 14 maintained at or near room temperature during the deposition step. The deposition is carried out in the absence of any solvent or catalyst for the polymer, and in the absence of any other action to aid polymerization. One preferred derivative for carrying out the deposition step is dichloro-di-p-xylylene. The parylene or parylene derivative is preferably applied at the thickness disclosed above, to yield a coating layer 16 which is substantially nonporous, but in any event less porous than the at least one porous layer 20 to be applied. If required by the composition of the coating layer 16, the layer 16 is then surface processed in an appropriate manner, for example, by plasma treatment as disclosed above.

The at least one layer 18 of the desired bioactive material or materials is then applied to the one surface of the structure 12, and in particular, onto the additional coating layer 16. This application step can be carried out in any of a variety of convenient ways, such as by dipping, rolling, brushing or spraying a fluid mixture of the bioactive material onto the additional coating layer 16, or by electrostatic deposition of either a fluid mixture or dry powder of the bioactive material, or by any other appropriate method. Different bioactive agents may be applied to different sections or surfaces of the device.

It can be particularly convenient to apply a mixture of the bioactive material or materials and a volatile fluid over the structure, and then remove the fluid in any suitable way, for example, by allowing it to evaporate. When heparin and/or dexamethasone or its derivatives serve as the bioactive material(s), the fluid is preferably ethyl alcohol. The bioactive material is preferably applied in an amount as disclosed above.

Other methods of depositing the bioactive material layer 18 over the structure 12 would be equally useful. Without regard to the method of application, however, what is important is that the bioactive material need only be physically held in place until the porous layer 20 is deposited over it. This can avoid the use of carriers, surfactants, chemical binding and other such methods often employed to hold a bioactive agent on other devices. The additives used in such methods may be toxic, or the additives or methods may alter or degrade the bioactive agent, rendering it less effective, or even toxic itself. Nonetheless, if desired these other methods may also be employed to deposit the bioactive material layer 18 of the present invention.

The bioactive material may, of course, be deposited on the one surface of the structure 12 as a smooth film or as a layer of particles. Moreover, multiple but different bioactive materials may be deposited in a manner that different surfaces of the device contain the different bioactive agents. In the latter case, the particle size may affect the properties or characteristics of the device 10, such as the smoothness of the uppermost porous coating 20, the profile of the device 10, the surface area over which the bioactive material layer 18 is disposed, the release rate of the bioactive material, the formation of bumps or irregularities in the bioactive material layer 18, the uniformity and strength of adhesion of the bioactive material layer 18, and other properties or characteristics. For example, it has been useful to employ micronized bioactive materials, that is, materials which have been processed to a small particle size, typically less than 10 μm in diameter. However, the bioactive material may also be deposited as microencapsulated particles, dispersed in liposomes, adsorbed onto or absorbed into small carrier particles, or the like.

In still another embodiment according to the present invention, the bioactive material may be posited on the one surface of structure 12 in a specific geometric pattern. For example, the tips or arms of a stent may be free of bioactive material, or the bioactive material may be applied in parallel lines, particularly where two or more bioactive materials are applied to the same surface.

In any event, once the bioactive material layer 18 is in place, the at least one porous layer 20 is then applied over the at least one bioactive material layer 18 in the same manner as for the application of the at least one additional coating 16. A polymer such as parylene or a parylene derivative is applied at the lesser thickness disclosed above, however, so as to yield the at least one porous layer 20.

Any other layers, such as the second bioactive material layer 22 or the additional porous layer 24, are applied in the appropriate order and in the same manner as disclosed above. The steps of the method are preferably carried out with any of the bioactive materials, structures, and base materials disclosed above.

Of course, polyimide may be deposited as any or all of the porous and additional coating layers 20, 24 and/or 16 by vapor deposition in a manner similar to that disclosed above for parylene and its derivatives. Techniques for the plasma deposition of polymers such as poly(ethylene oxide), poly(ethylene glycol), poly(propylene oxide), silicone, or a polymer of methane, tetrafluoroethylene or tetramethyl-disiloxane on other objects are well-known, and these techniques may be useful in the practice of the present invention.

Another technique for controlling the release of the bioactive material may include depositing monodispersed polymeric particles, i.e., referred to as porogens, on the surface of the device 10 comprising one or more bioactive materials prior to deposition of porous layer 20. After the porous layer 20 is deposited and cured, the porogens may be dissolved away with the appropriate solvent, leaving a cavity or pore in the outer coating to facilitate the passage of the underlying bioactive materials.

The method of using the device 10 of the present invention in medically treating a human or veterinary patient can now be easily understood as well. The method of the present invention is an improvement over previous methods which include the step of inserting into a patient an implantable vascular device 10, the device 10 comprising a structure 12 adapted for introduction into the vascular system of a patient, and the structure 12 being composed of a base material 14. The method according to the present invention comprises the preliminary steps of depositing at least one layer 18 of a bioactive material on one surface of the structure 12, followed by depositing at least one porous layer 20 over the at least one bioactive material layer 18, the porous layer 20 being composed of a polymer and having a thickness adequate to provide a controlled release of the bioactive material when the device 10 is positioned in the patient's vascular system.

The method can further entail carrying out the two depositing steps with the various embodiments of the device 10 disclosed above, in accordance with the method of making the device 10 disclosed above. More particularly, the step of depositing the at least one porous layer 20 can comprise polymerizing the at least one layer 20 from a monomer vapor, preferably a vapor of parylene or a parylene derivative, free of any solvent or catalyst. The method can also comprise the step of depositing the at least one additional coating layer 16 between the structure 12 and the at least one bioactive material layer 18.

The method of treatment according to the present invention is completed by inserting the device 10 into the vascular system of the patient. The at least one porous layer 20 and any additional porous layers 24 automatically release the bioactive material or materials in a controlled fashion into the patient.

The remaining details of the method of medical treatment are the same as those disclosed with respect to the method of making the device 10 of the present invention; for the sake of brevity, they need not be repeated here.

In view of the disclosure above, it is clear that the present invention provides an implantable medical device which achieves precise control over the release of one or more bioactive materials contained in the device. Moreover, the polyimide, parylene, parylene derivative or other polymeric layers 16, 20 and/or 24 can be remarkably thin, in comparison to the thicknesses required for other polymer layers. The bulk or substantial majority of the overall coating on the structure 12 can therefore consist of bioactive material. This allows the supply of relatively large quantities of bioactive material to the patient, much greater than the amounts supplied by prior devices. These quantities of bioactive material can be supplied to any of a wide variety of locations within a patient during or after the performance of a medical procedure, but are especially useful for preventing abrupt closure and/or restenosis of a blood vessel by the delivery of an antithrombic or other medication to the region of it which has been opened by PTA. The invention permits the release rate of a bioactive material to be carefully controlled over both the short and long terms. Most importantly, any degradation of the bioactive material which might otherwise occur by other polymer coating techniques is avoided.

The other details of the construction or composition of the various elements of the disclosed embodiment of the present invention are not believed to be critical to the achievement of the advantages of the present invention, so long as the elements possess the strength or flexibility needed for them to perform as disclosed. The selection of these and other details of construction are believed to be well within the ability of one of ordinary skills in this area, in view of the present disclosure.

INDUSTRIAL APPLICABILITY

The present invention is useful in the performance of vascular surgical procedures, and therefore finds applicability in human and veterinary medicine.

It is to be understood, however, that the above-described device is merely an illustrative embodiment of the principles of this invention, and that other devices and methods for using them may be devised by those skilled in the art, without departing from the spirit and scope of the invention. It is also to be understood that the invention is directed to embodiments both comprising and consisting of the disclosed parts. It is contemplated that only part of a device need be coated. Furthermore, different parts of the device can be coated with different bioactive materials or coating layers. It is also contemplated that different sides or regions of the same part of a device can be coated with different bioactive materials or coating layers.

Citat från patent
citerade patent Registreringsdatum Publiceringsdatum Sökande Titel
US4101984 *5 maj 197625 jul 1978Macgregor David CCardiovascular prosthetic devices and implants with porous systems
US4872867 *28 feb 198910 okt 1989Ube Industries, Ltd.Compositions having antithrombogenic properties and blood contact medical devices using the same
US5059166 *11 dec 198922 okt 1991Medical Innovative Technologies R & D Limited PartnershipIntra-arterial stent with the capability to inhibit intimal hyperplasia
US5108424 *28 jan 199128 apr 1992Meadox Medicals, Inc.Collagen-impregnated dacron graft
US5112457 *23 jul 199012 maj 1992Case Western Reserve UniversityPolyvinylpyrrolidone hydroxylated by reduction of the carbonyl group with sodium borohydride
US5197977 *30 apr 199230 mar 1993Meadox Medicals, Inc.Drug delivery collagen-impregnated synthetic vascular graft
US5282823 *19 mar 19921 feb 1994Medtronic, Inc.Intravascular radially expandable stent
US5304121 *22 nov 199119 apr 1994Boston Scientific CorporationCatheter
US5314688 *9 feb 199324 maj 1994Eli Lilly And CompanyLocal delivery of dipyridamole for the treatment of proliferative diseases
US5344444 *2 jul 19926 sep 1994Industrial Research B.V.Expandable ring, cylinder or sleeve which can be made non-deformable
US5348873 *19 okt 199220 sep 1994K.K. VayuImmobilization of an anti-thrombogenic substance with a photo-reactive azide and a photo-crosslinking material
US5356433 *3 nov 199318 okt 1994Cordis CorporationBiocompatible metal surfaces
US5383927 *15 apr 199324 jan 1995Intervascular Inc.Non-thromogenic vascular prosthesis
US5383928 *19 aug 199324 jan 1995Emory UniversityCardiovascular disorders
US5419760 *11 okt 199430 maj 1995Pdt Systems, Inc.Medicament dispensing stent for prevention of restenosis of a blood vessel
US5443458 *3 dec 199322 aug 1995Advanced Cardiovascular Systems, Inc.Multilayered biodegradable stent and method of manufacture
US5447724 *15 nov 19935 sep 1995Harbor Medical Devices, Inc.Has tissue exposed portion to release agent inhibiting adverse reaction to its presence; polymeric surface layer over reservoir; blood oxygenator
US5449382 *2 mar 199412 sep 1995Dayton; Michael P.Minimally invasive bioactivated endoprosthesis for vessel repair
US5455040 *19 nov 19923 okt 1995Case Western Reserve UniversityReduces thrombogenicity of substrate
US5457113 *15 okt 199310 okt 1995Eli Lilly And CompanyMethods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5464650 *26 apr 19937 nov 1995Medtronic, Inc.Intravascular stent and method
Citat från andra källor
Hänvisning
1 *Bruce Humphrey, Using Parylene for Medical Substrate Coating, Jan./Feb. 1996 Medical Plastics and Biomaterials.
2 *Photodynamic Therapy Application Approved, Feb. 15, 1996, Biomedical Technology Information Service.
3 *R.D. Falb, G.A. Grode, M.T. Takahashi and R.I. Leininger, Characteristics of Heparinized Surfaces, Oct. 11, 1968, Interaction of Liquids at Solid Substrates.
4 *Sushil Sheth, Vishva Dev, Harvey Jacobs, James S. Forrester, Frank Litvack, Neal L. Eigler, Prevention of Subacute Stent Thrombosis by Polymer Polyethylene Oxide Heparin Coating in the Rabbit Carotid Artery, Feb. 1995, JACC, 1001 29.
5Sushil Sheth, Vishva Dev, Harvey Jacobs, James S. Forrester, Frank Litvack, Neal L. Eigler, Prevention of Subacute Stent Thrombosis by Polymer-Polyethylene Oxide-Heparin Coating in the Rabbit Carotid Artery, Feb. 1995, JACC, 1001-29.
Hänvisningar finns i följande patent
citeras i Registreringsdatum Publiceringsdatum Sökande Titel
US6338739 *22 dec 199915 jan 2002Ethicon, Inc.Helical structure, coils, cores and coverings
US635855623 jan 199819 mar 2002Boston Scientific CorporationDrug release stent coating
US6395326 *31 maj 200028 maj 2002Advanced Cardiovascular Systems, Inc.Apparatus and method for depositing a coating onto a surface of a prosthesis
US6423092 *20 aug 200123 jul 2002Ethicon, Inc.Multilayer; interior core, exterior covering
US6440166 *16 feb 200027 aug 2002Omprakash S. KolluriMultilayer and multifunction vascular graft
US64513734 aug 200017 sep 2002Advanced Cardiovascular Systems, Inc.Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US6468304 *15 jul 199822 okt 2002Centre National De La Recherche ScientifiqueImplantable device covered with polymer capable of releasing biologically active substances
US647198013 feb 200129 okt 2002Avantec Vascular CorporationIntravascular delivery of mycophenolic acid
US6491617 *30 dec 199910 dec 2002St. Jude Medical, Inc.Medical devices that resist restenosis
US649490822 dec 199917 dec 2002Ethicon, Inc.Removable stent for body lumens
US649764614 mar 200124 dec 2002Cordis CorporationIntravascular radiotherapy source ribbon having variable radiopacity
US650355628 dec 20007 jan 2003Advanced Cardiovascular Systems, Inc.Depositing polymeric sheath prosthesis, prosthesis having interconnected struts separated by gaps and longitudinally extending central bore for allowing a fluid to travel through prosthesis; exposing sheath to heat to form a coating
US650395421 jul 20007 jan 2003Advanced Cardiovascular Systems, Inc.Biocompatible carrier containing actinomycin D and a method of forming the same
US6514284 *20 apr 20004 feb 2003Advanced Cardiovascular Systems, Inc.Stent having inner flow channels
US651788828 nov 200011 feb 2003Scimed Life Systems, Inc.Using ultrashort energy pulses to form high precision openings in stents; nondamaging; no polishing or cleaning required
US654077628 dec 20001 apr 2003Advanced Cardiovascular Systems, Inc.Sheath for a prosthesis and methods of forming the same
US661676510 jan 20029 sep 2003Advanced Cardiovascular Systems, Inc.Apparatus and method for depositing a coating onto a surface of a prosthesis
US6638259 *28 okt 199928 okt 2003Scimed Life Systems, Inc.Biocompatible medical devices
US663830223 dec 199728 okt 2003Sorin Biomedica Cardio S.P.A.Surface sculpturing, preferably on its outer surface only, constituted, for example, by microspheres, having the function of increasing the actual geometric surface area of the stent, of creating undercuts and roughness to encourage the
US6663606 *14 feb 200016 dec 2003Scimed Life Systems, Inc.Biocompatible medical devices
US666366228 dec 200016 dec 2003Advanced Cardiovascular Systems, Inc.Diffusion barrier layer for implantable devices
US666388030 nov 200116 dec 2003Advanced Cardiovascular Systems, Inc.Stents
US666962114 mar 200130 dec 2003Cordis CorporationMethod and assembly for containing radioactive materials
US668574515 maj 20013 feb 2004Scimed Life Systems, Inc.Delivering an agent to a patient's body
US669928118 jul 20022 mar 2004Sorin Biomedica Cardio S.P.A.Angioplasty stents
US6702849 *13 dec 19999 mar 2004Advanced Cardiovascular Systems, Inc.Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
US671284524 apr 200130 mar 2004Advanced Cardiovascular Systems, Inc.Coating for a stent and a method of forming the same
US671311923 dec 199930 mar 2004Advanced Cardiovascular Systems, Inc.Comprising an ethylene-vinyl alcohol copolymer; coated balloon-expandable stents, self-expandable stents, and grafts
US671644428 sep 20006 apr 2004Advanced Cardiovascular Systems, Inc.Barriers for polymer-coated implantable medical devices and methods for making the same
US673376825 jun 200211 maj 2004Advanced Cardiovascular Systems, Inc.Coated expandable stent
US674962617 nov 200015 jun 2004Advanced Cardiovascular Systems, Inc.Actinomycin D for the treatment of vascular disease
US675307127 sep 200122 jun 2004Advanced Cardiovascular Systems, Inc.Rate-reducing membrane for release of an agent
US675905428 dec 20006 jul 2004Advanced Cardiovascular Systems, Inc.Ethylene vinyl alcohol composition and coating
US678042430 mar 200124 aug 2004Charles David ClaudeControlled morphologies in polymer drug for release of drugs from polymer films
US679022828 dec 200014 sep 2004Advanced Cardiovascular Systems, Inc.Coating prosthetics; delivering active material
US680005521 feb 20015 okt 2004Cordis CorporationLow attenuating radioactive seeds
US6808250 *29 dec 199726 okt 2004Konica CorporationProduction method of ink-jet head
US681824727 apr 200116 nov 2004Advanced Cardiovascular Systems, Inc.Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent
US682455922 dec 200030 nov 2004Advanced Cardiovascular Systems, Inc.Ethylene-carboxyl copolymers as drug delivery matrices
US683315331 okt 200021 dec 2004Advanced Cardiovascular Systems, Inc.Hemocompatible coatings on hydrophobic porous polymers
US683538711 jun 200228 dec 2004Scimed Life Systems, Inc.In polymeric matrix; controlling releasing
US68490892 okt 20021 feb 2005Biotronik Mess-Und Therapiegeraete Gmbh & Co Ingenieurbuero BerlinImplant with proliferation-inhibiting substance
US6866656 *24 jan 200215 mar 2005Becton, Dickinson And CompanyLubricious coating for a medical device
US689058321 nov 200110 maj 2005Surmodics, Inc.Bioactive agent release coating
US689696512 nov 200224 maj 2005Advanced Cardiovascular Systems, Inc.Stents comprising protective coating including interpenetrating polymer network of acrylic acid-ethylene glycol copolymer; drug
US690862224 sep 200221 jun 2005Boston Scientific Scimed, Inc.Optimized dosing for drug coated stents
US690862416 dec 200221 jun 2005Advanced Cardiovascular Systems, Inc.Coating for implantable devices and a method of forming the same
US691376225 apr 20015 jul 2005Mayo Foundation For Medical Education And ResearchNon-woven framework containing pores having an average size of at least 40 mu m and metal or polymer fibers; stents
US6918869 *2 dec 200219 jul 2005Scimed Life SystemsSystem for administering a combination of therapies to a body lumen
US691892731 okt 200119 jul 2005Cook IncorporatedCoated implantable medical device
US692691926 feb 20039 aug 2005Advanced Cardiovascular Systems, Inc.coating with a blend of hydrophilic and hydrophobic polymers, where the hydrophilic polymer is migrated to the outer surface of the coating; stents
US69329304 nov 200323 aug 2005Synecor, LlcIntraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same
US693937513 feb 20016 sep 2005Avantac Vascular CorporationApparatus and methods for controlled substance delivery from implanted prostheses
US693937720 aug 20016 sep 2005Thoratec CorporationCoated vascular grafts and methods of use
US6945994 *5 dec 200120 sep 2005Boston Scientific Scimed, Inc.Combined balloon-expanding and self-expanding stent
US69819878 maj 20013 jan 2006Ethicon, Inc.Removable stent for body lumens
US698200426 nov 20023 jan 2006Advanced Cardiovascular Systems, Inc.Electrostatic loading of drugs on implantable medical devices
US698689912 aug 200317 jan 2006Advanced Cardiovascular Systems, Inc.Providing formulation of therapeutic substance and a first fluid in which therapeutic substance has limited solubility and being suspended as particles; applying to surface of prosthesis; removing fluid from prosthesis to form coating
US69890714 aug 200324 jan 2006Boston Scientific Scimed, Inc.formed by covering tube or mandrel with channel material, forming channel having two open ends by exposing covered tube to heat treatment, chemical treatment or treatment with adhesive, and attaching channel to side wall; drug delivery
US700866710 okt 20027 mar 2006Surmodics, Inc.Comprises polybutylmethacrylate and ethylene-vinyl acetate copolymer; for flexible catheters and stents; drug delivery
US701486124 okt 200321 mar 2006Advanced Cardiovascular Systems, Inc.Permeabilizing reagents to increase drug delivery and a method of local delivery
US701840513 feb 200128 mar 2006Avantec Vascular CorporationIntravascular delivery of methylprednisolone
US7018411 *18 feb 200228 mar 2006Implantcast Gmbhbone replacement; alloy support; electroplating
US702233420 mar 20024 apr 2006Advanced Cardiovascular Systems, Inc.Therapeutic composition and a method of coating implantable medical devices
US702237212 nov 20024 apr 2006Advanced Cardiovascular Systems, Inc.Compositions for coating implantable medical devices
US703338916 okt 200125 apr 2006Scimed Life Systems, Inc.Tubular prosthesis for external agent delivery
US704113030 jan 20049 maj 2006Boston Scientific Scimed, Inc.Stent for controlled release of drug
US704514227 sep 200416 maj 2006Boston Scientific Scimed, Inc.Metal-chelate compound in polymer matrix
US704893911 mar 200223 maj 2006The Board Of Trustees Of The Leland Stanford Junior UniversityMethods for the inhibition of neointima formation
US70524888 aug 200330 maj 2006Boston Scientific Scimed, Inc.Implantable drug delivery device
US705633911 mar 20026 jun 2006The Board Of Trustees Of The Leland Stanford Junior UniversityDrug delivery platform
US705659130 jul 20036 jun 2006Advanced Cardiovascular Systems, Inc.Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US707059019 sep 20004 jul 2006Massachusetts Institute Of TechnologyMicrochip drug delivery devices
US708364225 jul 20021 aug 2006Avantec Vascular CorporationDelivery of therapeutic capable agents
US708711513 feb 20038 aug 2006Advanced Cardiovascular Systems, Inc.Nozzle and method for use in coating a stent
US70872639 okt 20028 aug 2006Advanced Cardiovascular Systems, Inc.Polymer coating for drug elution stent; cardiovascular disorders
US709785018 jun 200229 aug 2006Surmodics, Inc.Coating includes the bioactive agent in combination with a first polymer component such as polyalkyl(meth)acrylate, polyaryl(meth) acrylate and a second polymer component such as poly(ethylene-co-vinyl acetate) for catheters and stents
US71153004 feb 20043 okt 2006Advanced Cardiovascular Systems, Inc.Method of coating implantable medical devices
US71220483 maj 200217 okt 2006Scimed Life Systems, Inc.Hypotube endoluminal device
US716032115 jun 20049 jan 2007Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US716356229 jan 200216 jan 2007Ethicon, Inc.Biodegradable stent
US716613427 sep 200223 jan 2007Ethicon, Inc.Biodegradable stent
US716918724 jun 200330 jan 2007Ethicon, Inc.Biodegradable stent
US716940430 jul 200330 jan 2007Advanced Cardiovasular Systems, Inc.biologically resorbable ABA or AB block copolymer and an active agent conjugated to the block copolymer, such as a diazenium diolate
US717587318 jul 200213 feb 2007Advanced Cardiovascular Systems, Inc.Rate limiting barriers for implantable devices and methods for fabrication thereof
US717587430 nov 200113 feb 2007Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US71792832 nov 200120 feb 2007Scimed Life Systems, Inc.Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom
US71792897 jun 200420 feb 2007Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US720193517 sep 200210 apr 2007Advanced Cardiovascular Systems, Inc.Plasma-generated coatings for medical devices and methods for fabricating thereof
US72081907 nov 200324 apr 2007Abbott LaboratoriesDispenser capable of controlling trajectory of discrete droplets; precise dosaging; applying multiple incompatible or reactive drugs
US721110823 jan 20041 maj 2007Icon Medical Corp.Can serve as a carrier for a very broad range of drugs, possibly including every drug presently used, being considered for use, or likely to be used in the future to inhibit stenosis
US72111509 dec 20021 maj 2007Advanced Cardiovascular Systems, Inc.Apparatus and method for coating and drying multiple stents
US722328227 sep 200129 maj 2007Advanced Cardiovascular Systems, Inc.Remote activation of an implantable device
US723257326 sep 200219 jun 2007Advanced Cardiovascular Systems, Inc.Stent coatings containing self-assembled monolayers
US7247338 *21 nov 200224 jul 2007Regents Of The University Of MinnesotaProviding a medical device and monodisperse coating particles in a defined volume; moving coating particles towards the at least one surface of the medical device to form a coating thereon
US724736425 feb 200524 jul 2007Advanced Cardiovascular Systems, Inc.Coating for implantable medical devices
US725589126 feb 200314 aug 2007Advanced Cardiovascular Systems, Inc.Method for coating implantable medical devices
US726194614 nov 200328 aug 2007Advanced Cardiovascular Systems, Inc.Block copolymers of acrylates and methacrylates with fluoroalkenes
US727932225 mar 20049 okt 2007Regents Of The University Of MinnesotaElectrospraying apparatus and method for coating particles
US728528715 sep 200323 okt 2007Synecor, LlcCarbon dioxide-assisted methods of providing biocompatible intraluminal prostheses
US72886094 mar 200330 okt 2007Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices based on poly (orthoesters)
US729432918 jul 200213 nov 2007Advanced Cardiovascular Systems, Inc.Poly(vinyl acetal) coatings for implantable medical devices
US731893230 sep 200315 jan 2008Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same
US732320915 maj 200329 jan 2008Advanced Cardiovascular Systems, Inc.applying a coating composition including a solvent to the stent;adjusting the temperature of the mandrel assembly to change the temperature of the stent such that the evaporation rate of the solvent is modified
US732321023 jun 200329 jan 2008Advanced Cardiovascular Systems, Inc.Method for depositing a coating onto a surface of a prosthesis
US73294136 nov 200312 feb 2008Advanced Cardiovascular Systems, Inc.Polymer layer and a second polymer layer, wherein the first polymer or the second polymer comprises a polyorthoester, stents
US73353915 dec 200326 feb 2008Advanced Cardiovascular Systems, Inc.With a polymeric solution containing paclitaxel, docetaxel, rapamycin, or dexamethasone at elevated temperatures in a pressurized chamber to increase the evaporation rate of the solvent; stents; restenosis
US733855717 dec 20024 mar 2008Advanced Cardiovascular Systems, Inc.Nozzle for use in coating a stent
US734156928 jan 200511 mar 2008Ekos CorporationTreatment of vascular occlusions using ultrasonic energy and microbubbles
US734163026 jun 200311 mar 2008Advanced Cardiovascular Systems, Inc.Stent coating system
US734449016 maj 200518 mar 2008Boston Scientific Scimed, Inc.System for administering a combination of therapies to a body lumen
US73445631 mar 200418 mar 2008Sorin Biomedica Cardio S.R.L.Angioplasty stents
US73446015 jan 200518 mar 2008Boston Scientific Scimed, Inc.Integrated cross-wire fixture for coating a device, a method of using the fixture, and a device made using the fixture
US736307420 aug 200222 apr 2008Advanced Cardiovascular Systems, Inc.Implanting a drug delivery device coated with polymer layer prepared from a compound having methylene-based chain reactive functional group(s) (octadecyl isocyanate or 1-octadecanol); becomes less crystalline when exposed to electrical stimulus, increasing rate of drug release
US737810618 dec 200627 maj 2008Advanced Cardiovascular Systems, Inc.drug polymer conjugates used as biodegradable coatings on medical equipment such as stents
US739049729 okt 200424 jun 2008Advanced Cardiovascular Systems, Inc.Poly(ester amide) filler blends for modulation of coating properties
US739052420 maj 200424 jun 2008Advanced Cardiovascular Systems, Inc.coating the exteriors of medical equipment, by mounting on support in a configuration such that it shields out external static electrical fields, then charging and applying the charged coatings onto the medical equipment
US739653826 sep 20038 jul 2008Endovascular Devices, Inc.Biocompatible polymer drug release matrix comprising a thermoplastic polyurethane elastomer and drug (quinone-containing alkylating agents of a mitomycin family) incorporated into the biocompatible polymer matrix; inhibit proliferation of smooth muscle cells causing restenosis
US739948029 okt 200415 jul 2008Abbott LaboratoriesMethods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US740232026 aug 200522 jul 2008Vnus Medical Technologies, Inc.Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
US740497930 sep 200229 jul 2008Advanced Cardiovascular Systems Inc.Spin coating apparatus and a method for coating implantable devices
US741374615 maj 200719 aug 2008Advanced Cardiovascular Systems, Inc.Stent coatings containing self-assembled monolayers
US743195931 jul 20037 okt 2008Advanced Cardiovascular Systems Inc.Method and system for irradiation of a drug eluting implantable medical device
US743872220 sep 200221 okt 2008Advanced Cardiovascular Systems, Inc.Method for treatment of restenosis
US744151326 sep 200328 okt 2008Advanced Cardiovascular Systems, Inc.apparatus for plasma polymerize coating of medical devices, such as stents, is disclosed. A method for forming plasma-polymerized coating for implantable medical devices is also disclosed such as stents
US744576610 apr 20064 nov 2008Microchips, Inc.Miniaturized device; substrate with reservoirs, openings; barriers layer covering aperture
US744921015 aug 200511 nov 2008Advanced Cardiovascular Systems, Inc.Electrostatic loading of drugs on implantable medical devices
US745585310 sep 200225 nov 2008Abbott Cardiovascular Systems Inc.Medical devices containing rapamycin analogs
US745587611 jul 200725 nov 2008Advanced Cardiovascular Systems, Inc.using computers to control dispensers used for applying coatings to medical equipments such as stents
US745590711 apr 200625 nov 2008Advanced Cardiovascular Systems Inc.Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7473273 *22 jan 20026 jan 2009Medtronic Vascular, Inc.Stent assembly with therapeutic agent exterior banding
US748515115 dec 20033 feb 2009Boston Scientific Scimed, Inc.Delivering an agent to a patient's body
US748831625 jan 200610 feb 2009Microchips, Inc.Improved delivery of drug formulations, protein drugs, from implanted medical devices, drug is stored as a solid or in concentrated, rather than dilute, solutions; decreased time required for dose of a drug formulation to be released from device; inhibition of gelation, aggregation, or precipitation
US748834316 sep 200310 feb 2009Boston Scientific Scimed, Inc.Medical devices
US749122516 feb 200517 feb 2009Boston Scientific Scimed, Inc.System and method for deploying a drug-eluting external body and tissue scaffold
US74912343 dec 200217 feb 2009Boston Scientific Scimed, Inc.Medical devices for delivery of therapeutic agents
US749806312 jul 20043 mar 2009Regents Of The University Of MinnesotaSprays of particles are established from the nozzle structures by creating a nonuniform electrical field between the nozzles and an electrically isolated electrode; for producing multiple sprays of particles, e.g., nanoparticles, for various applications including pharmaceuticals
US750412528 dec 200117 mar 2009Advanced Cardiovascular Systems, Inc.System and method for coating implantable devices
US75074333 sep 200424 mar 2009Boston Scientific Scimed, Inc.Method of coating a medical device using an electrowetting process
US751057119 aug 200331 mar 2009Boston Scientific, Scimed, Inc.Pleated composite ePTFE/textile hybrid covering
US753120216 jun 200612 maj 2009Advanced Cardiovascular Systems, Inc.Nozzle and method for use in coating a stent
US753446422 mar 200719 maj 2009Advanced Cardiovascular Systems Inc.Apparatus and method for coating and drying multiple stents
US75362216 mar 200819 maj 2009Advanced Cardiovascular Systems, Inc.Polymer layer having a crystalline structure; the polymer structure becomes less crystalline when exposed to a stimulus, when the stimulus is terminated, the structure returns to the same degree of crystallinity; implantable medical device
US7550005 *14 aug 200223 jun 2009Cook IncorporatedCoated implantable medical device
US756049225 nov 200314 jul 2009Advanced Cardiovascular Systems, Inc.stent has a coatings containing a copolymer of polysulfone and an elastomeric polymer, selecting from additional monomers as isobutylene, butyl methacrylate, lauryl methacrylate, or polyethersulfone copolymer, acrylated resins; mechanical properties, optimal permeability and good biocompatibility
US756348322 feb 200521 jul 2009Advanced Cardiovascular Systems Inc.Methods for fabricating a coating for implantable medical devices
US758551612 nov 20018 sep 2009Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US758864229 nov 200415 sep 2009Advanced Cardiovascular Systems, Inc.Abluminal stent coating apparatus and method using a brush assembly
US758879421 sep 200715 sep 2009Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices based on poly (orthoesters)
US759776417 aug 20066 okt 2009Abbott LaboratoriesSystem of loading beneficial agent to a prosthesis by fluid-jet
US760138425 aug 200613 okt 2009Advanced Cardiovascular Systems, Inc.Method of coating implantable medical devices
US760469918 jan 200820 okt 2009Advanced Cardiovascular Systems, Inc.Stent coating apparatus
US76048313 jun 200820 okt 2009Advanced Cardiovascular Systems Inc.Stent spin coating method
US7607208 *7 maj 200327 okt 2009Sorin Biomedica Cardio S.R.L.Method of making a medicated stent
US7611532 *14 aug 20023 nov 2009Cook IncorporatedCoated implantable medical device
US7611533 *19 aug 20023 nov 2009Cook IncorporatedCoated implantable medical device
US761451022 dec 200810 nov 2009Ws Packaging Group, Inc.Point of purchase display
US76221462 nov 200624 nov 2009Advanced Cardiovascular Systems, Inc.Coating a medical device such as a stent with a drug-containing polymer layer (e.g., ethylene-vinyl alcohol copolymer) and a formulation comprising a second polymer and a solvent; being a poor solvent for the therapeutic substance or the first polymer for preventing a significant migration of drug
US764547431 jul 200312 jan 2010Advanced Cardiovascular Systems, Inc.Mixing polymer and flux removal fluid, in particular a chlorofluoropropane, in extruder, removing at least a volume of fluid from extruder such that an impurity is completely or at least partially removed with the fluid, and coating an implantable medical device with the purified polymer
US764547623 apr 200712 jan 2010Abbott LaboratoriesUse of dispenser capable of controlling trajectory of discrete droplets; precise dosaging; applying multiple incompatible or reactive drugs
US764550426 jun 200312 jan 2010Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
US764847811 mar 200819 jan 2010Ekos CorporationTreatment of vascular occlusions using ultrasonic energy and microbubbles
US764852721 feb 200719 jan 2010Cook IncorporatedMethods of reducing retrograde flow
US765169518 maj 200126 jan 2010Advanced Cardiovascular Systems, Inc.For management of stenosis or restenosis following vascular trauma or disease
US76587582 mar 20059 feb 2010Innovational Holdings, LlcMethod and apparatus for loading a beneficial agent into an expandable medical device
US767814312 nov 200316 mar 2010Advanced Cardiovascular Systems, Inc.Ethylene-carboxyl copolymers as drug delivery matrices
US768264725 jun 200323 mar 2010Advanced Cardiovascular Systems, Inc.Exposing dry coating on device to a temperature greater than ambient temperature, dry coating comprising a polymer, an active agent, and residual fluid, wherein duration of exposure is sufficient to decrease release rate of agent from the coating after coating has been implanted into a biological lumen
US76826483 nov 200323 mar 2010Advanced Cardiovascular Systems, Inc.Addition polymerization of unsaturated monomers by heat treatment or exposure to ultraviolet radiation in presence of initiator; acrylation, endcapping
US770065924 mar 200520 apr 2010Advanced Cardiovascular Systems, Inc.Implantable devices formed of non-fouling methacrylate or acrylate polymers
US77045447 okt 200327 apr 2010Advanced Cardiovascular Systems, Inc.Minimizing defects, uniform thickness; employing applicator and rotation transferring technique
US771354113 nov 200711 maj 2010Abbott Cardiovascular Systems Inc.Biocompatible terpolymers include a zwitterionic monomer( phosphorylcholine methacrylate), an alkoxy acrylate (e.g.2-methoxyethyl methacrylate), hydrophobic monomer ( butyl methacrylate); dissolving terpolymer in an organic solvent, coating the implantable stent, drying; improved biocompatability
US7713552 *19 dec 200111 maj 2010Cook Biotech IncorporatedRadiopaque implantable collagenous biomaterial device
US773253523 mar 20058 jun 2010Advanced Cardiovascular Systems, Inc.Polyethylene-vinyl alcohol terpolymer modified by alkylation, esterification, introduction of fluorinated alkyl fragments, polysiloxane fragments; drug delivery; stents, heart valve, cerebrospinal fluid shunts, vascular graft, arterial puncture closure devices and pacemaker leads
US773978127 mar 200722 jun 2010Sorin Biomedica Cardio S.R.LProcess for producing a stent for angioplasty
US77495544 jan 20086 jul 2010Advanced Cardiovascular Systems, Inc.Method for coating stents
US775863614 mar 200520 jul 2010Innovational Holdings LlcExpandable medical device with openings for delivery of multiple beneficial agents
US775889112 dec 200820 jul 2010Abraxis Bioscience, LlcCombinations and modes of administration of therapeutic agents and combination therapy
US776330813 dec 200427 jul 2010Advanced Cardiovascular Systems, Inc.Method of regulating temperature of a composition for coating implantable medical devices
US7766881 *27 feb 20043 aug 2010Roche Diagnostics International AgImplant with surface structure
US776692630 apr 20033 aug 2010Vance Products IncorporatedSling for supporting tissue
US777053615 apr 200810 aug 2010Advanced Cardiovascular Systems, Inc.Coating abluminal surfaces of stents and other implantable medical devices
US777146816 sep 200310 aug 2010Angiotech Biocoatings Corp.Medicated stent having multi-layer polymer coating
US778064731 okt 200724 aug 2010Cook IncorporatedMedical device with therapeutic agents
US778155119 nov 200724 aug 2010Abbott LaboratoriesCopolymer of methoxyethyl or ethoxyethyl (meth)acrylate and a (meth)acrylic acid ester, amide or thioester containing a zwitterionic group, such as choline, phosphoryl choline, phosphorylethanolamine, phosphatidylethanolamine, phosphatidylserine, or sulfobetaine; ductility and toughness; stent coating
US778565325 jun 200431 aug 2010Innovational Holdings Llcsuch as a stent with holes, dispensing drug through dispenser in dropwise manner, andcontrolling local environment surrounding dispensing tip to prevent clogging by delivering shield gas (inert gases) adjacent the tip
US780772226 nov 20035 okt 2010Advanced Cardiovascular Systems, Inc.Biobeneficial coating compositions and methods of making and using thereof
US78198203 feb 200626 okt 2010Bard Peripheral Vascular, Inc.Self contained, self piercing, side-expelling marking apparatus
US782470415 aug 20052 nov 2010Surmodics, Inc.Controlled release bioactive agent delivery device
US785494112 feb 200821 dec 2010The University Of Southern MississippiPolytetrafluoroethylene (PTFE), polyoxyethylene glycol (PEG), maleic anhydride (MA), and penicillin (ampicillin or gentamicin) are reacted to yield penicillin-PEG-MA-PTFE, which inhibits Grampositive bacteria
US78582945 apr 200728 dec 2010Honeywell International Inc.Contacting silica dielectric film with plasma comprising at least one surface modification agent, at a concentration and for a time period effective to render the silica dielectric film hydrophobic; imparting hydrophobicity to both new and damaged silica dielectric films
US786260527 nov 20064 jan 2011Med Institute, Inc.Coated implantable medical device
US78716586 feb 200818 jan 2011Advanced Cardiovascular Systems, Inc.polymer such as polylactic acid can include a drug, and a solvent ( ethanol, dimethylsulfoxide) for coating the stent can be discharged from separate tubes disposed within another tube carrying moving air, polymer and the solvent mix together when they are discharged and are atomized by the air
US787506921 sep 200625 jan 2011Boston Scientific Scimed, Inc.Stent with support element
US787507321 nov 200625 jan 2011Advanced Cardiovascular Systems, Inc.Block copolymers of acrylates and methacrylates with fluoroalkenes
US787528427 jun 200725 jan 2011Cook IncorporatedMethods of manufacturing and modifying taxane coatings for implantable medical devices
US787528515 jul 200325 jan 2011Advanced Cardiovascular Systems, Inc.Medicated coatings for implantable medical devices having controlled rate of release
US78790812 okt 20061 feb 2011Boston Scientific Scimed, Inc.Hypotube endoluminal device and method
US787938714 jan 20081 feb 2011Cook IncorporatedProcess of electrostatically coating a stent on a catheter
US788787128 aug 200815 feb 2011Advanced Cardiovascular Systems, Inc.Method and system for irradiation of a drug eluting implantable medical device
US789222121 jan 200522 feb 2011Massachusetts Institute Of TechnologyMethod of controlled drug delivery from implant device
US790139731 okt 20078 mar 2011Massachusetts Institute Of TechnologyMethod for operating microchip reservoir device
US790613311 maj 200515 mar 2011Boston Scientific Scimed, Inc.Optimized dosing for drug coated stents
US7909864 *2 jul 200822 mar 2011Boston Scientific Scimed, Inc.Implantable medical devices having adjustable pore volume and methods for making the same
US791067819 nov 200722 mar 2011Abbott LaboratoriesCopolymers having 1-methyl-2-methoxyethyl moieties
US791515912 aug 200529 mar 2011Honeywell International Inc.Treating agent materials
US791518126 jan 200429 mar 2011Honeywell International Inc.Repair and restoration of damaged dielectric materials and films
US791884220 feb 20045 apr 2011Massachusetts Institute Of TechnologyMedical device with controlled reservoir opening
US791907520 mar 20025 apr 2011Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US79191088 mar 20075 apr 2011Cook IncorporatedPost-deposition treatment of medical device coatings including a taxane therapeutic agent; durability to withstand stent crimping and delivery procedures; drug delivery; cyclodextrin derivatives; stents; paclitaxel; free of a polymer; controlled release
US79191627 jun 20055 apr 2011Synecor, LlcIntraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same
US792807916 okt 200619 apr 2011The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPolysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
US792817619 nov 200719 apr 2011Abbott LaboratoriesCopolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers
US792817719 nov 200719 apr 2011Abbott LaboratoriesAmino acid mimetic copolymers and medical devices coated with the copolymers
US79412126 mar 200810 maj 2011Advanced Cardiovascular Systems, Inc.Method of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure
US79453196 mar 200817 maj 2011Advanced Cardiovascular Systems, Inc.Methods of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure
US79460196 maj 201024 maj 2011Sorin Biomedica Cardio S.R.L.Process for producing a stent for angioplasty
US795142831 jan 200731 maj 2011Regents Of The University Of MinnesotaElectrospray coating of objects
US795538214 sep 20077 jun 2011Boston Scientific Scimed, Inc.Endoprosthesis with adjustable surface features
US796785518 nov 200528 jun 2011Icon Interventional Systems, Inc.Coated medical device
US797235425 jan 20065 jul 2011Tyco Healthcare Group LpMethod and apparatus for impeding migration of an implanted occlusive structure
US79726614 okt 20075 jul 2011Regents Of The University Of MinnesotaElectrospraying method with conductivity control
US797686215 aug 200512 jul 2011Surmodics, Inc.Longitudinal body; polymeric coating of polyalkyl(meth)acrylate and/or aromatic poly(meth)acrylate; and poly(ethylene-co-vinyl acetate); triamcinolone acetonide; drug delivery to eye
US799339027 feb 20049 aug 2011Boston Scientific Scimed, Inc.Implantable or insertable medical device resistant to microbial growth and biofilm formation
US800192631 aug 200923 aug 2011Abbott LaboratoriesSystem and method of loading and detecting beneficial agent on a prosthesis
US80031235 maj 200823 aug 2011Advanced Cardiovascular Systems, Inc.Biologically absorbable coatings for implantable devices and methods for fabricating the same
US800362112 sep 200823 aug 2011Nitto Denko CorporationDrug carriers
US80078555 jul 200730 aug 2011Advanced Cardiovascular Systems, Inc.Method for coating implantable medical devices
US800785830 jan 200930 aug 2011Advanced Cardiovascular Systems, Inc.System and method for coating implantable devices
US80168817 sep 200413 sep 2011Icon Interventional Systems, Inc.Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US801714115 dec 200613 sep 2011Advanced Cardiovascular Systems, Inc.Coatings of acrylamide-based copolymers
US80171422 jun 200913 sep 2011Advanced Cardiovascular Systems, Inc.Polysulfone block copolymers as drug-eluting coating material
US802168029 apr 200420 sep 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US802864628 mar 20064 okt 2011Regents Of The University Of MinnesotaCoating medical devices
US802955719 jun 20094 okt 2011Vysera Biomedical LimitedEsophageal valve
US803411923 dec 200811 okt 2011Boston Scientific Scimed, Inc.Delivering an agent to a patient's body
US803436121 dec 200611 okt 2011Advanced Cardiovascular Systems, Inc.Stent coatings incorporating nanoparticles
US803436912 sep 200511 okt 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US803437521 feb 200611 okt 2011Abraxis Bioscience, LlcCombinations and modes of administration of therapeutic agents and combination therapy
US803870818 dec 200618 okt 2011Cook Medical Technologies LlcImplantable device with remodelable material and covering material
US80424863 jun 200825 okt 2011Advanced Cardiovascular Systems, Inc.Stent spin coating apparatus
US8043355 *29 dec 200825 okt 2011Taewoong Medical Co., Ltd.Double-tube type stent
US804815122 okt 20091 nov 2011Greatbatch Ltd.Stent coating for eluting medication
US804897510 mar 20111 nov 2011Abbott LaboratoriesAmino acid mimetic copolymers and medical devices coated with the copolymers
US80526585 okt 20068 nov 2011Bard Peripheral Vascular, Inc.Drug-eluting tissue marker
US805270815 dec 20088 nov 2011Bard Peripheral Vascular, Inc.Apparatus for the percutaneous marking of a lesion
US805298818 jan 20088 nov 2011Advanced Cardiovascular Systems, Inc.Implantantable medical stent with polymer coatings; first or second polymer is polyorthoester; second polymer has a higher degree of hydration than the first polymer; first, poly(butyleneterephthalate-co-ethylene glycol); second, poly(butyleneterephthalate-co-ethylene glycol)
US805298922 dec 20098 nov 2011Boston Scientific Scimed, Inc.Method of incorporating carbon nanotubes in a medical appliance, a carbon nanotube medical appliance, and a medical appliance coated using carbon nanotube technology
US8057543 *27 jan 200615 nov 2011Greatbatch Ltd.Stent coating for eluting medication
US806315119 nov 200722 nov 2011Abbott LaboratoriesMethods for manufacturing copolymers having 1-methyl-2-methoxyethyl moieties and use of same
US806498715 okt 200722 nov 2011C. R. Bard, Inc.Breast marker
US806676423 dec 200929 nov 2011Greatbatch Ltd.Stent coating for eluting medication
US807079618 nov 20056 dec 2011Icon Interventional Systems, Inc.Thrombosis inhibiting graft
US807170510 mar 20116 dec 2011Abbott LaboratoriesAmino acid mimetic copolymers and medical devices coated with the copolymers
US809282229 sep 200810 jan 2012Abbott Cardiovascular Systems Inc.Coatings including dexamethasone derivatives and analogs and olimus drugs
US809723620 feb 200217 jan 2012Psimedica LimitedThe invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable
US809726812 jun 200917 jan 2012Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US80972927 maj 200917 jan 2012Advanced Cardiovascular Systems, Inc,Methods for electrostatic coating of an abluminal stent surface
US810096328 dec 200624 jan 2012Icon Medical Corp.Biodegradable device
US810115619 nov 200724 jan 2012Abbott LaboratoriesMethods of manufacturing copolymers with zwitterionic moieties and dihydroxyphenyl moieties and use of same
US810120012 apr 200124 jan 2012Angiotech Biocoatings, Inc.Drug delivery; insertion at tumor site
US810552021 jan 200531 jan 2012Boston Scientific Scimed, Inc,Implantable or insertable medical device resistant to microbial growth and biofilm formation
US810923022 mar 20077 feb 2012Advanced Cardiovascular Systems, Inc.Apparatus and method for coating and drying multiple stents
US811024315 maj 20087 feb 2012Advanced Cardiovascular Systems, Inc.Coating for a stent and a method of forming the same
US811415210 nov 200814 feb 2012Icon Interventional Systems, Inc.Stent coating
US811442917 mar 201014 feb 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US81179848 jul 201021 feb 2012Advanced Cardiovascular Systems, Inc.Coating abluminal surfaces of stents and other implantable medical devices
US812411929 jul 200928 feb 2012Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US812869015 jul 20106 mar 2012Advanced Bio Prosthetic Surfaces, Ltd.Endoluminal device for in vivo delivery of bioactive agents
US812895124 feb 20106 mar 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US813739726 feb 200420 mar 2012Boston Scientific Scimed, Inc.Medical devices
US814283620 sep 201027 mar 2012Surmodics, Inc.Multi-layered coatings and methods for controlling elution of active agents
US81475405 jan 20113 apr 2012Cook Medical Technologies LlcTaxane coatings for implantable medical devices
US815315020 jun 200810 apr 2012Abbott LaboratoriesMethods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder
US815785416 jul 201017 apr 2012Boston Scientific Scimed, Inc.Method and system for delivery of coated implants
US8187620 *27 mar 200629 maj 2012Boston Scientific Scimed, Inc.Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US81927853 jan 20075 jun 2012Advanced Cardiovascular Systems, Inc.Apparatus and method for coating implantable devices
US820253028 nov 200519 jun 2012Advanced Cardiovascular Systems, Inc.Biocompatible coatings for stents
US820295610 mar 201119 jun 2012Abbott LaboratoriesCopolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers
US82114899 dec 20083 jul 2012Abbott Cardiovascular Systems, Inc.Methods for applying an application material to an implantable device
US822149527 nov 200617 jul 2012Abbott LaboratoriesIntegration of therapeutic agent into a bioerodible medical device
US823196218 jan 200831 jul 2012Advanced Cardiovascular Systems, Inc.Polymer layer and second polymer layer, comprises a polyorthoester; coatings for medical stent devices; improve biocompatibility and non-fouling properties, drug release rates
US82469748 apr 200521 aug 2012Surmodics, Inc.Medical devices and methods for producing the same
US8252044 *17 nov 200028 aug 2012Advanced Bio Prosthestic Surfaces, Ltd.Device for in vivo delivery of bioactive agents and method of manufacture thereof
US82574343 sep 20104 sep 2012Cormatrix Cardiovascular, Inc.Prosthetic tissue valve
US825772215 sep 20084 sep 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US825777710 apr 20084 sep 2012Boston Scientific Scimed, Inc.Overcoating medical equipment with photoresist polymer which may contain a drug
US82683488 sep 201118 sep 2012Abraxis Bioscience, LlcCombinations and modes of administration of therapeutic agents and combination therapy
US827792618 jan 20082 okt 2012Advanced Cardiovascular Systems, Inc.Methods for fabricating coatings for drug delivery devices having gradient of hydration
US82817379 mar 20049 okt 2012Boston Scientific Scimed, Inc.Coated medical device and method for manufacturing the same
US82820246 feb 20089 okt 2012Advanced Cardiovascular Systems, Inc.Stent coating nozzle assembly
US828298018 jan 20089 okt 2012Advanced Cardiovascular Systems, Inc.Stent coating method
US82875901 jul 201016 okt 2012Angiotech Biocoatings Corp.Medicated stent having multi-layer polymer coating
US830364824 apr 20076 nov 2012Cook Medical Technologies LlcArtificial venous valve containing therapeutic agent
US830911224 dec 200313 nov 2012Advanced Cardiovascular Systems, Inc.Segmented polyurethane comprising a soft segment and a hard segmentand an amphiphilic random or block copolymer for use in fabricating a coating for an implantable medical device such as a stent
US83128388 jul 201020 nov 2012Advanced Cardiovascular Systems Inc.Coating abluminal surfaces of stents and other implantable medical devices
US831381111 aug 201020 nov 2012Medos International S.A.R.L.Plasma enhanced polymer ultra-thin multi-layer packaging
US831381911 aug 201020 nov 2012Medos International S.A.R.L.Ultra-thin multi-layer packaging
US832333218 jan 20104 dec 2012Cook Medical Technologies LlcMethods of reducing retrograde flow
US83339849 aug 201118 dec 2012Abbott Cardiovascular Systems, Inc.Coatings of acrylamide-based copolymers
US83379376 jun 200825 dec 2012Abbott Cardiovascular Systems Inc.Stent spin coating method
US834935029 jul 20098 jan 2013Advanced Cardiovascular Systems, Inc.Coatings for drug delivery devices
US836114029 dec 201029 jan 2013Boston Scientific Scimed, Inc.High strength low opening pressure stent design
US83611437 jan 200929 jan 2013Boston Scientific Scimed, Inc.Medical devices for delivery of therapeutic agents
US83615389 dec 200829 jan 2013Abbott LaboratoriesMethods for applying an application material to an implantable device
US836153915 sep 200329 jan 2013Advanced Cardiovascular Systems, Inc.Adding a water soluble drug into a solution, combining a curing agent and adding into an oil bath
US836159111 aug 201029 jan 2013Medos International SarlPackaging with active protection layer
US836709112 jun 20095 feb 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US83671517 apr 20105 feb 2013Greatbatch Ltd.Stent coating for eluting medication
US8376980 *24 mar 201019 feb 2013David A. WatsonIngrowth preventing indwelling catheter assembly
US83771112 jan 200919 feb 2013Boston Scientific Scimed, Inc.Medical devices
US83774616 dec 200519 feb 2013Surmodics, Inc.Multifunctional medical articles
US83875538 jul 20105 mar 2013Advanced Cardiovascular Systems Inc.Coating abluminal surfaces of stents and other implantable medical devices
US838904117 jun 20105 mar 2013Abbott Cardiovascular Systems, Inc.Systems and methods for rotating and coating an implantable device
US839958410 mar 201119 mar 2013Abbott LaboratoriesCopolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers
US841965626 sep 200616 apr 2013Bard Peripheral Vascular, Inc.Post decompression marker introducer system
US843166523 feb 201030 apr 2013Abbott Cardiovascular Systems Inc.Zwitterionic terpolymers, method of making and use on medical devices
US8435286 *14 okt 20037 maj 2013Medtronic Vascular, Inc.Stent with intermittent coating
US844038828 nov 200514 maj 2013Honeywell International Inc.Method to restore hydrophobicity in dielectric films and materials
US844960726 jul 201228 maj 2013Cormatrix Cardiovascular, Inc.Prosthetic tissue valve
US84657584 maj 201018 jun 2013Abbott LaboratoriesDrug delivery from stents
US847566615 sep 20042 jul 2013Honeywell International Inc.Method for making toughening agent materials
US848113824 jan 20129 jul 2013Boston Scientific Scimed, Inc.Implantable or insertable medical device resistant to microbial growth and biofilm formation
US84871377 jul 201016 jul 2013Innovative Surface Technologies, LlcPhotochemical crosslinkers for polymer coatings and substrate tie-layer
US84919252 dec 201123 jul 2013Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US849670328 apr 201130 jul 2013Zuli Holdings Ltd.Amorphous metal alloy medical devices
US850082119 jun 20096 aug 2013Vysera Biomedical LimitedEsophageal valve device for placing in the cardia
US852414827 nov 20063 sep 2013Abbott LaboratoriesMethod of integrating therapeutic agent into a bioerodible medical device
US85342233 jan 201217 sep 2013Advanced Cardiovascular Systems, Inc.System for coating a stent
US855144618 sep 20078 okt 2013Advanced Cardiovascular Systems, Inc.Poly(vinyl acetal) coatings for implantable medical devices
US855151222 mar 20048 okt 2013Advanced Cardiovascular Systems, Inc.Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US855151716 dec 20088 okt 2013Kimberly-Clark Worldwide, Inc.Substrates providing multiple releases of active agents
US85630232 dec 201122 okt 2013Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US856302523 jan 200622 okt 2013Advanced Cardiovascular Systems, Inc.Coatings for implantable medical devices
US856943510 mar 201129 okt 2013Abbott LaboratoriesAmino acid mimetic copolymers and medical devices coated with the copolymers
US857315014 nov 20085 nov 2013Biosensors International Group, Ltd.Automated stent coating apparatus and method
US85901283 dec 201026 nov 2013Advanced Cardiovascular Systems, Inc.Selectively coating luminal surfaces of stents
US85915316 nov 200726 nov 2013Tyrx, Inc.Mesh pouches for implantable medical devices
US859156421 dec 201026 nov 2013Lifeshield Sciences, LLCHypotube endoluminal device and method
US859193414 nov 201226 nov 2013Abbott Cardiovascular Systems Inc.Coatings of acrylamide-based copolymers
US860318815 jul 201010 dec 2013Vysera Biomedical LimitedMedical device suitable for treating reflux from a stomach to an oesophagus
US860318915 jul 201010 dec 2013Vysera Biomedical LimitedMedical device suitable for treating reflux from a stomach to an oesophagus
US860353615 sep 200310 dec 2013Advanced Cardiovascular Systems, Inc.Microparticle coated medical device
US8616152 *6 aug 201231 dec 2013Abbott Cardiovascular Systems Inc.Stent coating apparatus
US863284128 feb 201321 jan 2014Abbott Cardiovascular Systems, Inc.Systems and methods for rotating and coating an implantable device
US86367538 feb 200728 jan 2014Tyrx, Inc.Temporarily stiffened mesh prostheses
US86476038 dec 201111 feb 2014Enigma Therapeutics LimitedDevices and methods for the treatment of cancer
US86587498 okt 200925 feb 2014Abbott LaboratoriesMethods for manufacturing amino acid mimetic copolymers and use of same
US8663311 *22 dec 20054 mar 2014Celonova Stent, Inc.Device comprising biodegradable bistable or multistable cells and methods of use
US867302020 jul 201218 mar 2014Vysera Biomedical LimitedEsophageal valve device for placing in the cardia
US867333227 jul 201218 mar 2014Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US867917614 sep 201225 mar 2014Cormatrix Cardiovascular, IncProsthetic tissue valve
US868543013 jul 20071 apr 2014Abbott Cardiovascular Systems Inc.Tailored aliphatic polyesters for stent coatings
US86897294 jan 20088 apr 2014Abbott Cardiovascular Systems Inc.Apparatus for coating stents
US86919831 mar 20108 apr 2014Innovative Surface Technologies, Inc.Brush polymer coating by in situ polymerization from photoreactive surface
US869673820 maj 201015 apr 2014Maquet Cardiovascular LlcComposite prosthesis with external polymeric support structure and methods of manufacturing the same
US869674424 maj 201215 apr 2014Cormatrix Cardiovascular, Inc.Extracellular matrix material valve conduit and methods of making thereof
US86971755 mar 201215 apr 2014Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc.Endoluminal device for in vivo delivery of bioactive agents
US871577118 sep 20096 maj 2014Abbott Cardiovascular Systems Inc.Coated stent and method of making the same
US872282615 apr 201313 maj 2014Abbott Cardiovascular Systems Inc.Zwitterionic terpolymers, method of making and use on medical devices
US873482517 jun 201327 maj 2014Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US87353946 maj 200927 maj 2014Abraxis Bioscience, LlcCombinations and modes of administration of therapeutic agents and combination therapy
US87397278 okt 20123 jun 2014Boston Scientific Scimed, Inc.Coated medical device and method for manufacturing the same
US875365920 maj 201317 jun 2014Abbott LaboratoriesDrug delivery from stents
US877920615 jul 201315 jul 2014Innovative Surface Technologies, LlcPhotochemical crosslinkers for polymer coatings and substrate tie-layer
US20120107403 *6 jan 20123 maj 2012Children's Medical Center CorporationBladder reconstruction
US20120172976 *15 mar 20125 jul 2012Cordis CorporationMethods and Devices for Delivering Therapeutic Agents to Target Vessels
US20120291703 *6 aug 201222 nov 2012Advanced Cardiovascular Systems, Inc.Stent coating apparatus
EP1300166A1 *25 sep 20029 apr 2003Cordis CorporationMeans for treatment of coronary artery obstructions
EP1314405A2 *26 sep 200228 maj 2003BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro BerlinGraft with proliferation-inhibiting substance
EP1498084A2 *21 sep 200119 jan 2005Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
EP1582180A1 *21 sep 20015 okt 2005Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
EP1839688A1 *28 mar 20063 okt 2007Universität ZürichDrug-eluting clinical device
EP1935380A1 *21 sep 200125 jun 2008Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
EP2103284A1 *21 sep 200123 sep 2009Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
EP2324866A214 jul 200325 maj 2011Cook IncorporatedAngioplasty balloons drug-coated in an expanded condition
EP2324867A114 jul 200325 maj 2011Cook IncorporatedAngioplasty balloons drug-coated in an expanded condition
EP2332493A127 jan 200515 jun 2011TriVascular, Inc.Inflatable porous implants and methods for drug delivery
EP2338538A1 *10 nov 200329 jun 2011Conor Medsystems, Inc.Method and apparatus for reducing tissue damage after ischemic injury
EP2407473A23 feb 200318 jan 2012ARIAD Pharmaceuticals, IncMethod for producing phosphorus-containing compounds
WO2002026162A2 *5 sep 20014 apr 2002Advanced Cardiovascular SystemA method of loading a substance onto an implantable device
WO2002032347A2 *21 sep 200125 apr 2002Conor Medsystems IncExpandable medical device for delivery of beneficial agent
WO2002085253A1 *19 apr 200231 okt 2002Univ Leland Stanford JuniorDrug delivery platform and methods for the inhibition of neointima formation
WO2002085424A1 *12 apr 200231 okt 2002Advanced Cardiovascular SystemA coating for a stent and a method of forming the same
WO2002091957A1 *9 maj 200221 nov 2002Scimed Life System IncDelivering an agent to a patient's body
WO2003043539A1 *26 sep 200230 maj 2003Scimed Life Systems IncTubular prosthesis for external agent delivery
WO2004028407A1 *24 sep 20038 apr 2004Scimed Life Systems IncMethod of applying coatings to a medical device
WO2004037443A1 *14 okt 20036 maj 2004Medtronic Vascular IncStent with intermittent coating
WO2004043509A1 *10 nov 200327 maj 2004Conor Medsystems IncExpandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
WO2004043510A1 *10 nov 200327 maj 2004Conor Medsystems IncMethod and apparatus for reducing tissue damage after ischemic injury
WO2006044307A212 okt 200527 apr 2006Boston Scient Scimed IncA magnetic levitation system for coating a device, a method of using the system, and device made by the system
WO2006063181A1 *6 dec 20056 dec 2005Surmodics IncMultifunctional medical articles
WO2007062320A2 *17 nov 200631 maj 2007Innovia LlcTrileaflet heart valve
WO2010033482A1 *15 sep 200925 mar 2010Innovative Surface Technologies, Inc.Drug eluting superhydrophobic coatings
WO2012088045A120 dec 201128 jun 2012Medtronic, Inc.Medical electrical lead having biological surface and methods of making and using same
WO2012142318A1 *12 apr 201218 okt 2012The Regents Of The University Of CaliforniaMultilayer thin film drug delivery device and methods of making and using the same
Klassificeringar
USA-klassificering623/1.39, 623/1.44, 604/508, 623/1.49, 623/23.71, 604/265
Internationell klassificeringA61L31/10, A61L29/16, A61F2/00, A61L31/00, A61B17/00, A61L29/08, A61M37/00, A61L33/02, A61K51/12, A61L31/08, A61N5/10, A61L27/30, A61L31/16, A61L27/54, A61L29/10, A61K9/00
Kooperativ klassningA61L33/022, A61L31/088, A61L29/16, A61L31/10, A61L29/085, A61L27/54, A61L29/106, A61L2300/602, A61L2300/608, A61L2300/42, A61N5/1002, A61L27/306, A61K51/1282, A61F2250/0068, A61L31/16
Europeisk klassificeringA61L31/16, A61L33/02B, A61K51/12T, A61L27/54, A61L27/30R, A61L29/16, A61L31/08B6, A61L31/10, A61L29/10R, A61L29/08B
Juridiska händelser
DatumKodHändelseBeskrivning
27 jan 2012FPAYFee payment
Year of fee payment: 12
15 jun 2011ASAssignment
Effective date: 20110314
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC., (D/B/A MED INSTITUTE, INC.);REEL/FRAME:026444/0958
Owner name: COOK MEDICAL TECHNOLOGIES LLC, INDIANA
17 maj 2011ASAssignment
Owner name: COOK MEDICAL TECHNOLOGIES LLC, INDIANA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COOK INCORPORATED;WILSON-COOK MEDICAL INCORPORATED;VANCEPRODUCTS INCORPORATED;AND OTHERS;SIGNING DATES FROM 20110315 TO 20110322;REEL/FRAME:026287/0923
7 jan 2008FPAYFee payment
Year of fee payment: 8
23 dec 2003FPAYFee payment
Year of fee payment: 4
16 maj 1996ASAssignment
Owner name: COOK INCORPORATED, INDIANA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAGHEB, ANTHONY O.;BATES, BRIAN L.;FEARNOT, NEAL E.;AND OTHERS;REEL/FRAME:007992/0936;SIGNING DATES FROM 19960508 TO 19960515
Owner name: MED INSTITUTE INC., INDIANA